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ABSTRACT
Archaea utilize the mevalonate (MVA) pathway for the biosynthesis of 
isopentenyl diphosphate (IPP) and its isomer, dimethylallyl diphosphate (DMAPP), the 
two building blocks of all isoprenoids. The archaeal MVA pathway deviates from the 
classical eukaryotic MVA pathway in the two-step conversion of mevalonate phosphate 
to IPP by utilizing a putative phosphomevalonate decarboxylase and the recently 
discovered isopentenyl phosphate kinase (IPK). The latter catalyzes the ATP-dependent 
phosphoryl transfer reaction to isopentenyl phosphate (IP) to form IPP.
Chen and Poulter recently characterized IPKs from Thermoplasma acidophilum 
(THA) and Methanothermobacter thermautotrophicus (MTH), using its substrate IP and 
other small molecule isoprenoid monophosphates. In this dissertation, we report the first 
crystal structures of THA and MTH IPKs in complex with their substrates and products. 
The structures reveal key active site residues involved in substrate binding and catalysis. 
We also describe the promiscuity of IPK towards fosfomycin, an antibiotic produced in 
Streptomyces and the substrate of the fosfomycin resistance enzyme, FomA. The 
structure of FomA is highly homologous to that of IPK, indicating a possible 
evolutionary relationship between the two enzymes. Finally, we describe four THA IPK 
mutants with kinase activities toward the longer chain isoprenoids geranyl phosphate 
(GP) and farnesyl phosphate (FP), achieved by mutations located in the IP binding site.
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The terpenoids, also known as isoprenoids, are a diverse family of naturally- 
occuring organic compounds derived from five-carbon isoprene units assembled and 
modified in thousands of ways to form mostly polycyclic structures with different carbon 
skeletons and functional groups. More than 60,000 terpenoids are known to date, acting 
as hormones (gibberellins, progesterone), structural components of cell membranes 
(cholesterol, ergosterol, hopanoids), electron transporters (haem A, ubiquinone), visual 
pigments (retinal), polysaccharide carriers for glycoprotein synthesis (dolichols), and 
protein modifiers for cellular localization (farnesylation and geranylgeranylation of Ras) 
(Figure 1.1) (1). In insects, two forms of the terpenoid farnesene act as semiochemicals: 
a-farnesene is an alarm pheromone in termites and food attractant for the coddling moth 
(2,3), while P-farnesene is an alarm pheromone in aphids that is released upon death (4). 
The plant genus Gardenia also produces a-farnesene as the chief chemical contributor to 
its scent (5). Other plant terpenoids act as photosynthetic pigments (chlorophyll), 
antimicrobial agents (phytoalexins) and as principal components of essential oils such as 





Farnesyl diphosphate alpha-farnesene beta-farnesene
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Figure 1.1 Chemical structures of representative examples of isoprenoids.
(lemon and orange oils) and camphor (incense). Some terpenoids are used in the 
treatment of cancer as well as protozoan, fungal and bacterial infections. For instance, 
artemisinin derivatives possess the most rapid action against falciparum and vivax 
malaria (6,7), while taxol, first isolated from the Pacific yew tree Taxus brevi/olia, is a 
mitotic inhibitor (8) used in the treatment of lung, ovarian, breast, head and neck cancer, 
and advanced forms of Kaposi’s sarcoma (9). The industrial manufacture of rubber and 
gutta-percha, perfumes, agrochemicals and food flavorings also depend on terpenoids as 
starting materials. Almost all organisms depend on terpenoids for surivival except for 
some endosymbiotic bacteria with very small genomes, as well as the archaeon 
Nanoarchaeum equitans that lives in an obligatory association with the 
hyperthermophilic crenarchaeote Ignicoccus hospitalis to obtain its lipids from the latter
(10).
Despite a vast array of chemical structures and functions, all terpenoid carbon 
backbones are derived from the five-carbon isoprene units isopentenyl diphosphate (IPP) 
and dimethylallyl disphosphate (DMAPP). The latter serves as the allylic primer for the 
head-to-tail condensation of IPP catalyzed by prenyltransferases, and subsequent 
additions of IPP produce the longer-chain isoprenoids geranyl diphosphate (GPP, Cio), 
farnesyl diphosphate (FPP, C15), geranyl geranyl diphosphate (GGPP, C20) and longer 
chain polyprenyl diphosphates (11,12). These compounds lie at major branch points in 
the isoprenoid biosynthetic pathway from which thousands of different polycyclic and 
acyclic terpenoids are generated (13,14).
Two independent and nonhomologous pathways for the biosynthesis of terpenoids 
are known: the mevalonate (MVA) pathway (Figure 1.2) and the 1-deoxy-D-xylulose-5-
3
Figure 1.2 The classical MVA pathway for isoprenoid biosynthesis.
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phosphate (DXP) pathway (Figure 1.3) (15). The MVA pathway is found in most 
eukaryotes (all mammals), fungi, archaea, some eubacteria, the mitochondria and cytosol 
of plants and Leishmania and Trypanosoma. The DXP pathway operates in plant 
chloroplasts, algae, cyanobacteria, eubacteria, and apicomplexan parasites.
The MVA Pathway
The MVA pathway was first elucidated in the 1950s by Bloch, Cornforth and 
Lynen for the biosynthesis of cholesterol in yeast and animals (15,16). As summarized in 
Figure 1.2, the pathway begins with the condensation of two molecules of acetyl CoA in 
a reaction catalyzed by acetoacetyl CoA thiolase. A third acetyl CoA is then condensed 
with acetoacetyl CoA by HMG CoA synthase to form 3-hydroxy-3-methylglutaryl-CoA 
(HMG CoA). The NADPH-dependent HMG CoA reductase then converts the CoA 
derivative to mevalonate, the rate-limiting step in the MVA pathway in humans. In ATP- 
dependent mechanisms, mevalonate then undergoes two successive phosphorylation steps 
catalyzed by mevalonate kinase (MK) and phosphomevalonate kinase (PMK). The 
diphosphate is subsequently decarboxylated by diphosphomevalonate decarboxylase 
(PPMD) to form IPP. To complete the MVA pathway, some of the IPP is converted to 
DMAPP by IPP isomerase.
Mevalonate, the product of HMG CoA reductase, is a key intermediate in the 
MVA pathway. It is used in the manufacture of cholesterol in the liver and intestines, and 
high cholesterol levels in the blood can damage arteries leading to cardiovascular 
diseases. To meet the physiological need for nonsterol isoprenoids without leading to 
cholesterol overaccumulation, several regulatory mechanisms exist, including the
5
Figure 1.3. The DXP or MEP pathway for isoprenoid biosynthesis.
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feedback regulation of HMG CoA synthase, HMG CoA reductase, and the LDL receptor
(11). In the absence of LDL, HMG CoA synthase and HMG CoA reductase have high 
activities, producing sufficient mevalonate for the synthesis of cholesterol and nonsterol 
isoprenoids (17). When LDL levels are high, the activities of the two enzymes are 
reduced by up to 90% and only small amounts of mevalonate are produced for nonsterol 
end products. When excess mevalonate is supplied externally together with LDL, residual 
HMG CoA reductase activity is abolished, terminating mevalonate production. The rise 
in sterol levels or decline in cholesterol demand results in the repression of the LDL 
receptor gene, preventing cholesterol overaccumulation (18). Other mechanisms can also 
regulate mevalonate biosynthesis, including sterol-mediated transcription regulation (19­
25) and posttranscriptional regulation of HMG CoA reductase (26-29). Phosphorylation 
of HMG CoA reductase also regulates the enzyme’s activity and can influence activities 
of other enzymes downstream (29-31).
Cells not only regulate mevalonate synthesis but also control mevalonate 
disposition. Nonsterol enzymes generally have higher affinities than sterol enzymes for 
mevalonate-derived substrates (17). At limiting concentrations of mevalonate, the 
synthesis of nonsterol isoprenoids is preferred. The committed step in sterol biosynthesis 
catalyzed by squalene synthetase is also suppressed upon prolonged incubation with 
sterols, thereby decreasing the incorporation of mevalonate into sterols.
With the central role of HMG CoA reductase in cholesterol metabolism and 
nonsterol isoprenoid biosynthesis, it is not surprising that it is one of the most highly 
regulated enzymes in nature. Inhibition of HMG CoA reductase by statins controls the 
production of cholesterol with benefits for lowering blood pressure, the treatment of
7
cardiovascular disease, and inflammatory processes. Lipitor, a statin, is the best-selling 
pharmaceutical in history with reported sales of more than $12.4 billion in 2008 (32).
The DXP Pathway
For many years it was believed that the MVA pathway was responsible for the 
biosynthesis of isoprenoids in all organisms. However, several findings were inconsistent
13with this idea. For instance, labeling studies did not incorporate [ C] acetate into 
ubiquinone in E. coli (33) or pentalenolactone in S. chromo/uschus (34,35). Feeding
13experiments using [U- C] glucose and pentalenolactone-producing S. ex/oliatus showed 
labeling patterns inconsistent with mevalonate-dependent synthesis (34,35). Moreover, 
the specific HMG CoA reductase inhibitor mevinolin did not suppress E. coli growth 
(33).
In the 1990s, Rohmer and Arigoni discovered the DXP pathway in E. coli (Figure 
1.3) (36), which begins with the thiamine-dependent condensation of pyruvate and 
glyceraldehyde-3-phosphate catalyzed by DXP synthase to produce deoxyxylulose 
phosphate (DXP) (16, 37). DXP is then converted to methylerythritol-5-phosphate (MEP) 
in the presence of NADH by DXP reductoisomerase. This reaction is the first committed 
step in the DXP pathway. MEP is then linked to CTP by MEP cytidylyltransferase to 
form cytidylyldiphosphomethylerythritol (CDP-ME), which is then phosphorylated by 
CDP-MEP kinase to yield cytidylyldiphosphomethylerythritol phosphate (CDP-MEP). 
Cyclomethylerythritoldiphosphate (cMEPP) synthase then eliminates CMP from CDP- 
MEP to form the cyclic product cMEPP, which is then reduced by 4- 
hydroxydimethylallyl diphosphate (HDMAPP) synthase. The reductive dehydration of
8
HDMAPP is then catalyzed by HDMAPP reductase to produce an approximately 5:1 
mixture of IPP and DMAPP (38). In the DXP pathway, IPP isomerase is not required to 
produce DMAPP from IPP. However, organisms harboring the DXP pathway still utilize 
IPP isomerase to balance the pools of IPP and DMAPP depending on current metabolic 
needs (39).
Possible evidence for feedback regulation of cMEPP synthase (also known as 
IspF) comes from crystallographic, NMR and mass spectrometric studies in which the 
enzyme is found to bind phosphate, IPP, DMAPP, geranyl diphosphate and farnesyl 
diphosphate, all of which are downstream products of the DXP pathway (40,41). 
However, there is currently no evidence for the global transcription regulation of DXP 
pathway genes as they are dispersed throughout genomes, in contrast with MVA pathway 
genes in some microorganisms that are organized into operons that are likely 
transcription regulated. On the other hand, the genes for MEP cytidylyltransferase (IspD ) 
and cMEPP synthase (IspF) are transcriptionally fused in some cases, coding for a 
bifunctional enzyme that can catalyze nonconsecutive steps in the pathway (37). IspDF 
can then form complexes with IspE to create an assembly of catalytic centers that can 
efficiently catalyze the three consecutive steps from MEP to cMEPP at the heart of the 
DXP pathway. Nonetheless, no evidence exists for rate enhancement by complex 
formation or substrate channeling (42,43).
DXP pathway enzymes are absent from mammals but present in important 
pathogens that cause malaria, tuberculosis and a variety of sexually transmitted diseases 
(15). For example, DXP enzymes in P. falciparum translocate to the apicoplast, an 
organelle of cyanobacterial origin absent from mammals (44,45). The substrates and
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products of DXP enzymes are also unique and their activities cannot be compensated for 
by another enzyme (46). These make them attractive targets for therapeutic intervention 
via specific drug inhibition. Fosmidomycin, for instance, is an inhibitor of DXP 
reductoisomerase and has been used effectively in combination with clindamycin for the 
treatment of malaria (47-50). The presence of DXP enzymes in plant chloroplasts also 
suggest them as suitable targets for herbicide development (37). Improved sources of 
secondary plant metabolites with medical importance such as artemisinin and taxol as 
well as other terpenoids used in essential oils and flavoring can also be developed by 
genetic manipulation of the DXP pathway (51).
Archaeal Cell Membrane Lipids
The three-domain classification scheme for all living things first emerged in the 
1970s with the discovery by Woese and coworkers of the third domain of life, called the 
Archaea (52). The development of molecular classification techniques enabled 
comparisons of ubiquitous sequences such as ribosomal proteins and RNAs that strongly 
suggested the early divergence of the archaeal and bacterial domains from within the 
prokaryotic lineage (53). Since then, a wealth of other findings obtained from 
comparisons of membrane lipid structures and genome sequences provided strong 
support to the existence of this third domain (54-57). Moreover, contrary to the previous 
understanding that archaeal organisms only thrived in extreme environments (high salt, 
low pH, high temperature), it was found that they also inhabit milder terrestrial and 
aquatic habitats (58,59).
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Isoprenoid membrane lipids are the key features of Archaea (60-65). Unlike the 
bacterial lipid bilayer composed of 16- to 18-carbon fatty acid side chains in ester 
linkages with glycerol, archaeal lipids contain ether-linked isoprenoid chains ranging in 
length from 20 to 40 carbon atoms. The most common archaeal membrane lipid is 
diphytanylglycerol diether (archaeol), which contains phytanyl chains consisting of 20 
carbon atoms. Archaeal membrane lipids with acyl chains of different lengths (e.g. C25) 
have also been observed (66,67). In another case, diphytanylglycerol tetraether 
(caldarchaeol) forms a lipid monolayer, where each lipid subunit consists of two 
hydrophilic groups connected by 40-carbon hydrophobic isoprene units (68). 
Modifications of the isoprenoid chain include formation of macrocyclic diether lipids by 
joining terminal methyl groups, a bridge between the alkyl chains or a break in one of the 
alkyl chains in tetraether lipids, introduction of pentacyclic rings (69), and addition of 
hydroxyl groups (Figure 1.4).
The composition of membrane lipids in various archaeal species can change in 
response to environmental factors. For example, in the hyperthermophilic archaea 
Thermococcus kodakarensis and Archaeoglobus fulgidus, increasing growth temperature 
leads to an increase in the caldarchaeaol to archaeol ratio (70,71). In 
Methanocaldococcus jannaschii, archaeols decreased and caldarchaeols and macrocyclic 
archaeols increased with increasing growth temperature (72). The number of 
cyclopentane rings also increases with increasing growth temperature in 
Thermoplasmatales and Sulfolobales (73-75). Several other examples of membrane lipid 
adaptations in archaea are known, although the molecular basis of this thermosensing and 
the resulting changes in membrane lipids remain to be elucidated.
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Figure 1.4. Examples of isoprenoid lipids found in Archaeal membranes. X represents 
sugars or other polar head groups. (a) sn-2,3-diacylglycerol-diether lipid (b) Glycerol- 
dialkyl-glycerol tetraether lipid (c) Common modifications of the isoprenoid side chain.
The differences between the archaeal and bacterial/eukaryotic membranes go 
beyond the structures of the lipid side chains. Whereas bacteria and eukaryotes utilize 
1,2-sn-glycerol, archaea utilize the other stereoisomer, 2,3-sn-glycerol (62, 65,76). This 
difference in stereochemistry is absolute with no known exception in any one of the three 
domains. As such, the ether-linked isoprenoid membrane lipids are the most clear-cut 
identifying features of Archaea (76, 77), which are also generally accepted to confer 
strength, stability and limited permeability to their membranes. Ether-linked lipids can be 
considered more chemically stable at low pH and high temperatures than ester-linked 
lipids, and branched isoprenoid chains can form more densely packed supramolecular 
structures that are more stable and less permeable than bacterial/eukaryotic membranes.
Although there is ample experimental evidence for the idea that ether-linked 
isoprenoid membranes are well suited to support life in extreme environments (78-80), 
there is no strict correlation between isoprenoid membranes and extremophilicity, as 
some archaea that live on nonextreme environments also harbor the same ether-linked 
isoprenoid lipids. Moreover, some thermophilic bacteria such as members of the 
hypertherm ophilic Aquifex and Thermotoga genera are known to contain a majority of 
ester-linked fatty acid membrane lipids in addition to ether-linked ones (81). In this case, 
the ether-linked lipids contain fatty acid side chains, not isoprenoids, with the same 
stereochemistry as bacterial/eukaryotic lipids.
The Archaeal Mevalonate Pathway
Of the seven enzymes required to synthesize IPP and DMAPP in eukaryotes, 
orthologs of only four have been identified in archaea, including acetoacetyl CoA
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thiolase, HMG CoA synthase, HMG CoA reductase, and MK (82). While orthologs of 
the eukaryotic type 1 IPP isomerase (IDI1) are generally absent from archaea except 
Halobacteriales, the nonorthologous enzyme that catalyzes the same reaction, type 2 IPP 
isomerase (IDI2), is found in all archaea including Halobacteriales (82). Thus, two 
enzymes required for the conversion of phosphomevalonate to IPP -  PMK and PPMD -  
are generally missing in archaea except in some restricted archaeal clades, perhaps as a 
result of horizontal gene transfer from eukaryotes or bacteria.
Within archaea, homologs of PMK and PPMD have only been identified in 
Sulfolobus (82). These enzymes are likely of eukaryotic origin as shown by phylogenetic 
analyses. Thermoplasmatales and Halobacteriales also possess homologs of PPMD, 
although both cluster in phylogenetic trees with bacterial PPMDs and not with Sulfolobus 
PPMD (82). Nonhomologous enzyme recruitment has been proposed by some authors to 
replace these missing enzymes in the archaeal MVA pathway, as is the case of the 
metazoan PMK similar to viral nucleoside monophosphate kinase instead of enzymes 
from the galactokinase, homoserine kinase, MK and PMK families (83,84). Another 
notable example is that of the nonhomologous IDI2 mentioned earlier. First discovered in 
Streptomyces sp. by Kaneda et al., this enzyme catalyzes the isomerization of IPP to 
DMAPP and is different from the mammalian IDI1 (85). IDI2 was later found to be 
encoded in the genomes of many archaea and was characterized in several of them 
(86,87). In addition, a search for enzymes in Methanocaldococcus jannaschii (MJ) able 
to phosphorylate phosphomevalonate led Grochowski et al. to identify a gene (MJ044) 
that codes for an enzyme with ATP-dependent kinase activity towards IP (88). The 
enzyme was assigned as isopentenyl phosphate kinase (IPK). Its gene is found in all
14
archaea except Nanoarchaea and clusters with other genes in the MVA pathway. 
Moreover, the IPKs from MJ, THA, and MTH have high catalytic efficiencies that are 
consistent with those of established enzymes in the MVA pathway. These observations 
led to the proposition of an alternate route in the archaeal MVA pathway in which the 
two steps for the conversion of phosphomevalonate to IPP are the reverse of those in the 
classical MVA pathway. This alternate pathway requires that a phosphomevalonate 
decarboxylase (PMD) precedes the final phosphorylation step, and that the MJ043 gene, 
which also clusters with other MVA pathway genes in archaea, is proposed to code for 
this enzyme (88). The decarboxylation reaction does not require a substrate with a 
diphosphate group so that the proposed alternate route can proceed from 
phosphomevalonate as the substrate of the putative PMD.
The Early Evolution of the Mevalonate Pathway in the 
Three Domains of Life
The dichotomy between the MVA pathway in eukaryotes and archaea and the 
DXP pathway in bacteria and plastid-bearing eukaryotes has been recognized for many 
years. However, the observations that archaea lacked the two enzymes used in the 
conversion of phosphomevalonate to IPP, as well as the presence of the MVA pathway in 
Firmicutes, raised some questions about the evolution of isoprenoid pathways in living 
things. Is the alternate MVA pathway conserved in archaea? Given the parsimonious 
nature of genomes and the identification of the MVA pathway in Firmicutes, is the MVA 
pathway rather than the DXP pathway ancestral to the bacterial domain? Phylogenetic 
studies performed by Lombard and Moreira showed that despite the complexity of the
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distribution of isoprenoid biosynthetic pathways in the three domains of life, there exists 
a clear preference for the DXP pathway in bacteria, the classical MVA pathway in 
eukaryotes and the alternate MVA pathway in archaea (89). Thus, instead of the two 
isoprenoid pathways distributed between the three domains and some cases of HGT 
among them, there is strong phylogenetic evidence for a tripartite distribution in which 
the alternate MVA pathway is considered a separate and conserved pathway in archaea. 
Despite these preferences, however, the same phylogenetic studies led Lombard and 
Moreira to hypothesize that the classical MVA pathway was likely present in the last 
universal common ancestor (LUCA) of all organisms and is therefore the ancestral 
isoprenoid pathway. A more detailed discussion of this analysis is presented below.
The Alternate MVA Pathway Is Conserved in Archaea
Phylogenetic analyses of MVA enzymes (except acetoacetyl CoA thiolase, which 
is not exclusive to this pathway) from a wide list of representative species showed that 
the alternate MVA pathway is characteristic of the whole archaeal domain (89). The first 
three enzymes HMGS, HMGR and MK showed a general topology consistent with the 
accepted phylogeny of organisms. For example, HMGS yielded phylogenetic trees with a 
well-supported separation of the eukaryotic, bacterial and archaeal sequences down to the 
level of phyla or classes, with the exception of the bacterial phylum Chloroflexi and the 
bacteriodete Flavobacterium johnsoniae whose HMGS sequences branched among the 
archaea, indicating HGT from this domain (89, Figure 2). The last three enzymes in the 
classical MVA pathway, PMK, PPMD and IDI1, did not exhibit this tridomain 
distribution since they are generally missing in archaea, with the exception of
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Haloarchaea and Thermoplasmatales, which have PPMD, and Haloarchaea and 
Thermautoarchaeota, which have IDI1 (89, Supplementary Figures 2-4). These PPMD 
and IDI1 homologues branched among the bacteria, suggesting their HGT from the 
bacterial domain. Moreover, the only PMK and PPMD sequences found in archaea 
(Sulfolobales) did not branch with those of either eukayotes or bacteria, but were in an 
intermediate position that suggests their ancestral presence only in Sulfolobales. 
Orthologues of IPK and IDI2 were also found in archaea with the other MVA pathway 
enzymes, except Sulfolobus tokodaii, Cenarchaeum symbiosum, Nitorospumilus 
maritimus and some halophilic archaea, where IDI2 is replaced by IDI1. Phylogeny of 
IDI2 sequences showed a separation between bacterial and archaeal sequences, except for 
the Firmicutes, which branched among the archaea (89, Supplementary Figure 5). In 
addition, IPK homologues could not be detected in the genomes of most species in other 
domains of life, with the exception of 14 eukaryotes and 9 bacteria (89). IPK sequences 
are less conserved across species compared to those of other MVA enzymes, leading to 
phylogenetic trees that were poorly supported and less congruent with the presumed 
phylogeny of organisms. However, removal of bacterial and eukaryotic IPK homologues 
led to better alignments and more supported trees with monophyletic archaeal classes. 
Thus, despite sporadic cases of HGT events, there is strong evidence of a conserved, 
modified MVA pathway for the biosynthesis of IPP and DMAPP in archaea (89).
An Ancestral MVA Pathway in Bacteria
The current availability of a larger sampling of complete bacterial genome 
sequences has led to the new finding that the classical MVA pathway is ancestral to
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bacteria despite the fact that the DXP pathway is now the dominant route for isoprenoid 
biosynthesis in this domain. MVA pathway enzymes have been identified not only in 
Firmicutes, but also in 93 bacterial species belonging to 43 different genera of 6 phyla 
(89). In particular, Firmicutes, Actinobacteria, Proteobacteria and the Spirochete genus 
Borrelia encode most of the enzymes in the MVA pathway. Bacteriodetes possess only 
some of the enzymes, while Chloroflexi contains IPK instead of PMK. IDI1 and IDI2, 
compulsory in the MVA pathway of eukaryotes and archaea, have been identified in 
bacteria, despite the presence of HDMAPP reductase, which is able to synthesize both 
IPP and DMAPP simultaneously. While it has been shown that in certain bacteria the 
IDIs complement defects in the synthesis of IPP in Fe-S protein biogenesis (90), their 
major role in Firmicutes is in isoprenoid biosynthesis. Bacteriodetes, some 
Actinobacteria, and some Proteobacteria employ IDI1, whereas Firmicutes, 
Cyanobacteria, Chlorobi, Chloroflexi, Deinococcus-thermus, Spirochetes, 
Deltaproteobacteria, and some proteobacterial and archaeobacterial species utilize IDI2. 
In addition, some bacteria contain either one of two classes of HMGR. Class II HMGR is 
more widespread and characteristic of many bacterial phyla and is considered ancestral in 
this domain. The Class I homologue is found in several Proteobacteria and 
Actinobacteria.
In phylogenetic analyses, the bacterial sequences of MVA pathway enzymes 
emerged as a monophyletic group distinct from the archaeal and eukaryotic clades. In 
fact, for each enzyme, the vast majority of bacterial sequences form an independent 
monophyletic group, as in the phylogenies of HMGS (89, Figure 2) and MK (89, Figure 
4). Biochemical characterizations of these enzymes also showed that they have distinct
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sequence signatures and biochemical properties. These indicate that contrary to the 
commonly accepted idea that bacteria obtained MVA pathway enzymes by HGT from 
archaeal or eukaryotic donors, the MVA pathway is ancestral to bacteria. Only in the 
cases of HMGS from Chloroflexi (89, Figure 2) and Flavobacterium johnsoniae, and 
IDI2 in Firmicutes that branch with the archaeal clade (89, Supplementary Figure 5) was 
the expected pattern of HGT observed, indicating that these bacterial organisms obtained 
some of their MVA enzymes from archaeal donors. Conversely, the Class II HMGR of 
euryarchaeota and thaumarchaeota clustered within the bacterial clade, signifying HGT 
from bacteria to archaea (89, Figure 3).
The apparent separation of bacterial MVA proteins from those of archaea and 
eukaryotes can be explained in three scenarios (89). First, an ancient bacterial lineage 
may have obtained the MVA pathway enzymes from an archaeal or bacterial donor, 
followed by a period of fast evolution that led to the high sequence divergence of the 
bacterial MVA enzymes from the original ones. This was followed by new HGT events 
that led to the presence of MVA pathway enzymes in today’s bacterial classes (Figure 
1.5a). The second scenario involves the inheritance of the entire MVA pathway from 
archaea or eukaryotes prior to the speciation of bacteria. In this case, the MVA pathway 
becomes ancestral to bacteria (Figure 1.5b). The third scenario assumes the presence of 
the MVA pathway from the cenancestor, so that vertical inheritance led eukaryotes, 
archaea and bacteria to possess an ancestral MVA pathway prior to the divergence of 
their respective sequences (Figure 1.5c). The last two scenarios require multifarious 
losses of MVA pathway genes from different bacterial lineages made possible by the
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Figure 1.5. Three hypotheses for the origin of MVA pathway enzymes in bacteria. (a) 
Horizontal transfer of the complete MVA pathway from eukaryotic or archaeal donors to 
a bacterial lineage and subsequent transfers from this lineage to bacterial groups currently 
utilizing the MVA enzymes (black branches). (b) Ancient horizontal transfer of the entire 
MVA pathway to a bacterial ancestor prior to the divergence of the contemporary 
bacterial phyla. (c) The cenancestor as the source of the MVA pathway present in some 
bacterial species. Scenarios (b) and (c) implies multiple losses of the MVA pathway in 
some bacterial phyla (grey branches). The classical rooting of the tree of life is used for 
convenience.
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functional redundancy of the MVA pathway with the DXP pathway present in most 
bacteria.
An Ancestral MVA Pathway in the Cenancestor
While there is a clear preference for the MEP pathway in bacteria, the classical 
MVA pathway in eukaryotes, and the alternative MVA pathway in archaea, phylogenetic 
analyses of MVA pathway enzymes by Lombard and Moreira support the possible 
presence of the classical MVA pathway in the cenancestor, subsequently inherited by 
each of the three domains of life (89). This hypothesis entails the massive loss of the 
classical MVA pathway enzymes in bacteria and its replacement by the MEP pathway, 
and in archaea, the early presence of the missing PMK and PPMD enzymes (Figure 1.6a). 
Thus, the current repertoire o f enzymes in both bacterial and archaeal domains is the 
result of both small-scale and large-scale nonhomologous replacement of enzymes in the 
classical MVA pathway. Still, two alternative hypotheses can explain the evolution of 
isoprenoid biosynthesis pathways. On the one hand, it is possible that the cenancestor had 
ancestral forms of each of the three different isoprenoid biosynthetic pathways, followed 
by selective losses in each domain of life to account for their unique differences (Figure 
1.6b). Worthy of note is the absence of MEP pathway enzymes in archaea and in 
nonplastid bearing eukaryotes, signifying that the common ancestor o f these two domains 
did not possess the MEP pathway. On the other hand, the cenancestor could also not have 
possessed any of the isoprenoid pathway enzymes and was therefore acellular (91,92) or 
devoid of a lipid membrane (93) (Figure 1.6c). This would entail that each isoprenoid 




Figure 1.6. Scenarios that explain the evolution of the different isoprenoid biosynthesis 
pathways on a schematic three domains of life tree. The eukaryotic and archaeal MVA 
pathways (MVA-Euk and MVA-Arc) are indicated in green and red, respectively, while 
the bacterial DXP pathway (here indicated as MEP) is indicated in blue. Stars indicate the 
origin of the respective pathways. (a) The classical MVA pathway would have been 
present in the cenancestor and supplanted in most bacteria and archaea by the MEP and 
the MVA-Arc pathways, respectively. (b) The three pathways would have been possessed 
by the cenancestor, but only one pathway would have been conserved in each domain of 
life. HGT events would explain the occurrence of supplementary pathways. (c) The 
cenancestor did not possess any of the three isoprenoid pathways, and each would have 
appeared in the ancestors of each domain life. Subsequent HGT events would explain the 
presence of MVA-Euk and MEP pathways in several bacteria and eukaryotes, 
respectively.
between the bacterial and eukaryotic domains. This hypothesis has been advanced by 
some authors, although it is remote because of the presence of fatty acid biosynthesis and 
degradation enzymes in archaea, as well as of dehydrogenases involved in glycerol-1- 
phosphate (G1P) and glycerol-3-phosphate (G3P) syntheses in archaea and bacteria, 
which argue that all the components required to create a lipid membrane (phospholipids 
composed of glycerol phosphate bound to lateral chains of isoprenoids or fatty acids) 
existed in the cenancestor (94). In other words, the differences in cellular membranes 
observed today are likely secondary and related to the divergence of the three domains of 
life.
Isopentenyl Phosphate Kinase
Isopentenyl phosphate kinase (IPK) is one of the missing enzymes in the alternate 
MVA pathway first discovered in MJ in 2006 by Grochowski et al. (88). Since then its 
homologues in THA and MTH have been kinetically characterized, including its substrate 
specificity, product formation, forward and reverse reactions, and pH- and temperature- 
activity profiles (95). IPK is the first enzyme found to catalyze the ATP-dependent 
phosphorylation of IP to form IPP in vitro (88). Although other enzymes in MJ display 
preference for GTP, MJ IPK strictly uses ATP. MJ IPK has an apparent KMIP of 256 .^M, 
with a kcat of 3.3 x 102 s-1. This KMIPis in line with the values measured for MK from rats, 
humans and MJ, which range from a KM RS-memlonate of 68 to 288 ^M. For MTH and THA, 
Kmip are 12.7 ^M and 4.4 .^M, respectively. All three enzymes have catalytic efficiencies 
comparable to other enzymes in the MVA pathway, suggesting their true roles as IP 
kinases (Table 1.1). Moreover, the phosphoryl transfer reaction has an equilibrium
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Table 1.1. Published kinetic constants of IPKs from MJ, MTH and THA.
Constant M J IPK MTH IPK THA IPK
-(sat 3.3 x 102 27.5 (± 0.3) 8.0 (± 0.2)
KmIP (mM) 256 12.7 (± 0.6) 4.4 (± 0.5)
KmATP (mM) not determined 13.4 (± 0.8) 6.0 (± 0.5)
K jP (mM) not determined 15.3 (± 2.6) 4.6 (± 1.5)
KdATP (mM) not determined 16.2 (± 2.5) 6.3 (± 2.2)
kcat/KjP (M-1 s-1) 1.3 x 106 2.2 x 106 1.3 x 106
constant Keq = 6.3, indicating that in vitro the forward reaction is only slightly preferred 
than the reverse reaction (95).
Published studies on IPKs confirmed their expected thermostability, with MJ IPK 
retaining 38% of its activity after incubation at 100 °C for 10 min, and MTH and THA 
IPKs remaining stable up to 50 °C and 70 °C, respectively. MJ IPK is active over a broad 
pH range between 7 and 9. MTH IPK prefers alkaline conditions while THA IPK prefers 
acidic conditions. The kcJ p values for MTH IPK are independent of pH from 7 to 9, 
which suggests a single rate-limiting step with the same ionization state throughout the 
tested pH range. In addition, the kcJ p/KMIP-pH profile for MTH IPK is bell-shaped, with 
two inflection points at pK1 = 6.7 for the acidic limb and pK2 = 9.9 for the basic limb. 
The pK1 likely corresponds to the ionization of the second proton of IP or o f a conserved 
histidine (His52). The pK2 of 9.9 may correspond to the ionization of any one of the 
conserved lysine residues in the active site (Lys5, Lys14 and Lys223, pK2 = 8.9 and pK3 
= 10.20) whose pKa value was perturbed by neighboring interactions in the active site. 
Likewise, the kcatIP/KMIP-pH activity profile for THA IPK is bell-shaped, with a pK1 for 
the acidic limb of 6.5 similar to that of MTH IPK, and pK2 for the basic limb of 8.5 that 
may also reflect the ionization of a conserved active site lysine residue (Lys5, Lys14 and 
Lys205). The kcat1P-pH profile for THA IPK is also bell-shaped, suggesting multiple 
ionization states for the enzyme-substrate complex within the experimental pH range of
5.5 to 9.0. In addition, kinetic analyses by Chen and Poulter showed that the binding of 
the substrates IP and ATP is sequential, although further experiments need to be 
performed in order to determine their binding order (95).
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A blastp search against the NCBI nonredundant protein database using the MJ 
IPK sequence as a query retrieved 107 enzymes belonging to the amino acid kinase 
(AAK) family, of which 78 are from Archaea (representing 21 different families within 
the domain), 21 from Eukarya and 8 from Bacteria. Among these, 5 are annotated as IP 
kinases and 2 as fosfomycin kinases (95). Enzymes in the AAK family catalyze the ATP- 
dependent phosphorylation of small molecules that contain phosphate, phosphonate, 
carboxylate and carbamate moieties that serve as the attacking nucleophile in the 
phosphoryl transfer reaction. MTH IPK has substantial sequence similarity with MJ IPK
29 13(e-value of 5e" ), while THA IPK was the most distant in sequence (e-value of 7e" ) 
among the retrieved homologues. Among the sequences are two fosfomycin kinases 
(FomA) from Streptomyces wedmorensis and Streptomyces fradiae, which are bacterial 
resistance enzymes capable of inactivating fosfomycin by the covalent modification of its 
phosphonate group. The crystal structure of S. wedmorensis FomA was recently 
determined and confirmed the putative binding and catalytic roles of several residues 
conserved in the alignment (96,97). Like FomA, IPK from either THA or MTH is 
dimeric and this oligomerization is presumed to be important for the stabilization of loops 
within the vicinity of the IP binding site. Archaeal IPK is not known to interact with 
another enzyme and its product IPP is relatively stable, precluding the use of dimerization 
for substrate channeling.
Alignment of the retrieved sequences showed that most of the residues known to 
perform binding and catalytic roles in well-studied AAK enzymes (e.g., N- 
acetylglutamate kinase or NAGK, 98) are partially or fully conserved in putative IPKs 
(95, Table S2). Worthy of note are two conserved residues, Lys14 and His50 in THA
26
IPK, that are absolutely conserved in putative archaeal IPKs and in FomA but not in other 
AAK enzymes (Figure 1.7). The corresponding histidine residue in S. wedmorensis 
FomA (His58) is seen in the crystal structure to interact with a phosphonate oxygen atom 
of fosfomycin through water-mediated hydrogen bonding, suggesting that it may have a 
role in the orientation of the substrate for nucleophilic attack on the donor nucleotide. In 
addition, His58 is located in the aB helix, a secondary structure seen only in FomA and 
UMPK (which does not have a corresponding histidine residue) (99) but not in other 
enzymes belonging to the AAK family. This residue may therefore be characteristic of 
IPKs and FomAs and may serve as a fingerprint for identifying homologs. This 
commonality between archaeal IPKs and bacterial FomAs may also suggest an early 
evolutionary relationship between the two enzymes. Finally, a lysine residue (Lys14 in 
THA) is conserved in putative IPK and FomA homologs (99). Recent structures of FomA 
as well as mutagenesis experiments showed that this conserved lysine residue is 
important for transition state stabilization of the negatively charged transition state (100).
MTH and THA IPKs have also been shown to efficiently phosphorylate a variety 
of C4 and C5 organic phosphates with kcat values comparable to the native substrate IP 
and slightly higher KM values in the mM range. For the C10 substrate geranyl phosphate, 
the kcat values are significantly lower (200-fold and 2000-fold lower for MTH and THA 
IPK, respectively) compared to native substrate, while the KM values are in the high mM 
to low mM range. The catalytic efficiencies of MTH and THA IPK for the 
phosphorylation of GP are, however, both similarly low (95).
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Figure 1.7. Active site of Streptomyces wedmorensis FomA, showing His58 and Lys14 
that are conserved only in FomA and putative IPKs.
Thesis Overview
So far, only a few profiling studies on IPK have been documented, including the 
kinetic characterizations briefly discussed above. While more kinetic experiments need to 
be performed in order to fully describe the catalytic mechanism of IPK (e.g., substrate 
binding order, substrate and product inhibition, cooperative binding kinetics observed in 
other AAK enzymes such as aspartokinase, mutagenesis studies to elucidate the roles of 
active site residues etc.), of utmost importance are three-dimensional structures of this 
enzyme that can reveal the residues important for substrate binding and catalysis. These 
structures will also locate residues found in sequence alignments to be partially or fully 
conserved, thus revealing the similarities and more importantly, the differences of IPK 
structures from those of other AAK enzymes whose three-dimensional structures have 
been determined. Finally, IPK structures can guide the structure-based engineering of the 
active site to create “new enzymes” or mutants capable of phosphorylating a variety of 
longer chain aliphatic or isoprenoid phosphates, such as geranyl phosphate or farnesyl 
phosphate and their analogues. These mutants can then be used as a tool for the 
radioactive labeling of the said longer-chain monophosphates that have potential 
applications in the studies of enzymes that use them as substrates, such as 
prenyltransferases and isoprenoid synthases.
The work described in this dissertation focuses on the crystal structure, substrate 
promiscuity and structure-based engineering of IPK. Chapter 2 describes the efforts in 
crystal structure determination of both MTH and THA IPK, in complex with their 
substrates and products. Chapter 3 then describes the studies done on the promiscuity of 
THA IPK for the antibiotic fosfomycin, where the results point toward a possible
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evolutionary relationship between IPK and FomA initiated by an ancient HGT event, a 
hypothesis first proposed by Chen and Poulter (95). Finally, Chapter 4 describes several 
THA IPK variants with apparent kinase activities toward the longer chain substrates, GP 
and FP.
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CHAPTER 2
X-RAY STRUCTURES OF ISOPENTENYL PHOSPHATE KINASE
Introduction
Kinases or phosphotransferases are enzymes that catalyze the transfer o f a 
phosphate group from a high-energy nucleotide donor such as ATP to a substrate. More 
than 500 kinases are known in humans, acting on small molecules such as lipids, 
carbohydrates, amino acids, and nucleotides to prime them for metabolic pathways or as 
part o f signaling processes. Protein kinases constitute one o f the largest groups of this 
type of enzymes, making up 2% of the human genome and modifying more than 30% of 
all human proteins (1). Phosphorylation occurs most commonly on the hydroxyl groups 
of serine and threonine, and less commonly on tyrosine and histidine, resulting in a 
change in enzyme activity, cellular location or association with other proteins. A 
malfunction of any of these regulatory machineries often leads to various diseases and 
disorders, including cancer.
A typical protein kinase contains a conserved core consisting of two lobes, a
smaller C-terminal lobe and a larger N-terminal lobe that together form a cleft that
2+ 2+accommodates Mg - or Mn -bound ATP (2,3). A glycine-rich loop (G-loop) covers the 
P- and y-phosphates of ATP and performs a critical role in phosphoryl transfer and in
ATP/ADP exchange during the catalytic cycle. The more rigid and primarily helical C- 
terminal lobe serves as a docking site for substrate peptides or proteins. The N-terminal 
part of the substrate peptide lies in a groove between the aD and aF helices on one side 
and the aG  helix on the other (Figure 2.1a). At the C-terminus of the substrate peptide, 
the residue right after the phosphorylated side chain is buried in a pocket formed by the 
P+1 loop, found at the C-terminus of an extended activation segment (Figure 2.1b). This 
segment is the most important regulatory element in protein kinases as it controls both 
substrate binding and catalytic efficiency. In the middle of this activation segment is the 
activation loop (also called the phosphorylation lip) that contains a serine, threonine or 
tyrosine residue that can be autophosphorylated or phosphorylated by other protein 
kinases. The APE motif at the C-terminus of the activation segment anchors the P+1 loop 
to the aF helix. This motif is conserved in almost all kinases and contains invariant Ala 
and Pro residues that bind to a conserved Trp residue in the aF helix (5-8).
The proper positioning of protein kinase elements ensures that ATP and the 
substrate peptide are precisely positioned for catalysis, especially since phosphoryl 
transfer is very sensitive to the distance between the reactants. This is achieved by the 
presence of two noncontiguous hydrophobic spines, called the C-spine (catalytic spine) 
and the R-spine (regulatory spine) that define the internal architecture and conformation 
of all protein kinases and provide a firm yet flexible scaffold for these elements (Figure 
2.2a and b). The C-spine starts at the C-terminus of the aF helix, traverses both lobes of 
the protein kinase molecule through a stretch of hydrophobic residues, and controls 
catalysis by localizing the ATP in its binding cleft. The R-spine, on the other hand, starts 
at a conserved Asp residue in the aF helix that hydrogen bonds with the main chain of
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Figure 2.1. General architecture of a protein kinase, using PDB structure 1ATP. (a) The 
N- and C-terminal lobes of protein kinase form a cleft for binding ATP. The divalent 
metals Mg2+ and Mn2+ are shown as red spheres. The glycine-rich loop (G-loop) forms a 
lid over the P- and y-phosphates of ATP and plays a role in phosphoryl transfer. The 
substrate peptide (grey) is located in the primarily helical C-terminal lobe, where its N- 
terminus is flanked by the aD  and aF  helix on one side and the aG  helix on the other. 
The activation segment is the most important regulatory element in protein kinases and 
consists of the P+1 loop, the activation loop (phosphorylation lip) and the APE motif at 
the C-terminus. (b). The substrate peptide is positioned next to the aF  helix by conserved 
hydrophobic residues in the activation segment. The P+1 loop forms a hydrophobic 
pocket anchored to Trp222 in the aF  helix via the APE motif. The phosphorylation site 
on the substrate is shown as a yellow sphere. The P-2 arginine residue anchors the 
peptide to the aF  helix by hydrogen bonding with Glu230.
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Figure 2.2. Two hydrophobic spines anchored to the aF  helix that define the internal 
architecture of all protein kinases. Both spines span the N- and C-termini of the molecule 
through a series of side chains from non-contiguous secondary structures in the enzyme. 
(a) The catalytic spine (C-spine) is shown as a yellow surface. The R-spine is colored red. 
The gatekeeper residue (dark red) is located between the two spines and is spatially 
conserved. (b). Protein kinase in an open conformation. Efficient catalysis depends on the 
“breathing” of the protein kinase, during which both spines remain intact.
His/Tyr from the HRD motif, introducing a hydrophobic backbone of bulky residues 
found in the activation segment and the aC  helix. Formation of the R-spine depends on 
phosphorylation o f the activation segment, and all active protein kinases possess an R- 
spine while inactive ones do not. Interestingly, this spine model has allowed the 
identification of residues that occupy spatially conserved sites. One such example is a 
methionine “gatekeeper” residue, called as such because it was used to regulate the 
binding of unnatural ATP analogues (Figure 2.2a). While the gatekeeper residue is not 
conserved in all kinases and its side chain in many cases can be removed without loss o f 
kinase activity, its substitution can lock the R-spine in its active, closed form. For 
instance, mutation of the Thr gatekeeper residue in Src and Abl kinases to bulkier side 
chains such as methionine and isoleucine led to a constitutively active oncogenic kinase 
because of a permanently locked R-spine (9-15).
A smaller subset of the kinase family consists of enzymes that can phosphorylate 
small molecules with acyl groups, forming an acylphosphate. To date, four different 
“molecular machines” or structural devices are known to synthesize an acylphosphate 
product, having as paradigms NAGK, acetate kinase, phosphoglycerate kinase and biotin 
carboxylase, where each differs in architecture, domain folding and nucleotide binding 
(Figure 2.3). However, common among all enzymes in this subset are the short-chain 
carboxylic acid containing substrates, which are thought to have been among the most 
common organic molecules in prebiotic and early biotic environments. Acetic acid, for 
instance, has the interesting property o f  being capable o f  diffusing freely across 




Figure 2.3. Four different kinds of molecular devices for forming acylphosphate bonds 
are known and are exemplified by the following enzymes: phosphoglycerate kinase 
(2X15) (a), acetate kinase (1G99) (b), the biotin carboxylase subunit of acetyl coA 
carboxylase (1BNC) (c), and N-acetyl-L-glutamate kinase (1GS5) (d). Bound nucleotides 
are shown in stick representation.
Phosphoglycerate kinase (PGK) is required for ATP synthesis in the glycolytic 
pathways of aerobes and anaerobes as well as for carbon fixation in plants. PGKs are 
monomeric enzymes with molecular masses of around 45 kilodaltons, with comparable 
amino acid compositions and similar catalytic properties. The most striking feature of 
PGK is that its single polypeptide chain is organized into two widely separated domains 
of almost equal size that make large-scale hinge-bending conformational changes and 
domain closure broadly similar to that reported for hexokinase (Figure 2.3a). The N- 
terminal domain of the enzyme binds 3-phosphoglycerate while the C-terminal domain 
binds ATP. Each domain is composed of a central P sheet of six parallel strands 
surrounded by helices, although there are no significant similarities in their sequences 
and their detailed structures are different. As in other glycolytic enzymes, the overall 
tertiary structure is formed by the repetition of P-a units, which is repeated 12 times in 
PGK (17).
Acetate kinase (AK) represents the second type of acylphosphate-forming device. 
AK converts acetyl phosphate and ADP to acetate and ATP in the production of methane, 
and converts acetate to acetyl phosphate in the conversion of acetate to methane and 
carbon dioxide. The N-terminal domain of AK consists of an eight-stranded P sheet and 
eight a  helices, while the C-terminal domain consists of a seven-stranded P sheet, eleven 
helices and an additional small two-stranded P sheet (Figure 2.3b). The ATP binding site 
is located in the cleft between the two domains. The AK fold consists of a core identical 
to that of the glycerol kinase/hexokinase/actin/Hsc70 superfamily (also called the 
ASKHA superfamily). This core is composed of a duplicated PPPaPaPa secondary
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structure with insertions of subdomains between particular elements of the P sheet. The 
residues that bind the magnesium ion are also conserved among ASKHA enzymes (16).
Biotin carboxylase (BC) is a subunit of acetyl CoA carboxylase, which catalyzes 
the first committed step and one of the regulated steps in the biosynthesis of long-chain 
fatty acids. The subunit biotin carboxylase, on the other hand, catalyzes the biotin- 
dependent carboxylation of acetyl CoA to form malonyl CoA in a two-step reaction 
mechanism. Here, the reaction using bicarbonate and ATP forms a carboxyphosphate 
intermediate that collapses immediately into phosphate and CO2 with subsequent attack 
o f biotin on the latter. The BC monomer is asymmetric and consists o f  three structural 
motifs (Figure 2.3c). The N-terminal domain adopts a dinucleotide binding motif 
consisting of five strands of parallel P-pleated sheet flanked on either side by a total of 
four a  helices. This architecture is similar to that of NAD+-dependent dehydrogenases 
and UDP-galactose 4-epimerase and was unexpected since BC is ATP-dependent. In 
addition to the P strands and a  helices, the N-terminal domain contains six type I turns. 
The B domain follows the N-terminal domain and projects outward of the main body of 
the subunit. It contains two a  helices, three strands of antiparallel P sheets and flexible 
interconnecting loops rich in glycine residues. Finally, the C-terminal domain is an 
eight-stranded antiparallel P sheet with two P strands being disrupted by P bulges. It also 
contains a smaller three-stranded antiparallel P sheet, seven a  helices and seven reverse 
turns. The C-terminal domain cradles the N-terminal nucleotide-binding domain, forming 
a distinct cleft in the biotin carboxylase structure (18).
N-acetylglutamate kinase (NAGK) exemplifies the fourth kind of molecular 
device for making acylphosphates. It is part of a pathway in plants and microorganisms
47
that converts N-acetylated glutamate (NAG) to L-ornithine, the precursor of arginine. In 
animals, L-ornithine is produced by a similar pathway that utilizes nonacetylated 
glutamate. This differential trait and the fact that NAGK catalyzes an obligatory, and in 
many cases, controlling step in organisms that synthesize arginine via NAG, make it an 
appropriate target for selective inhibition of arginine biosynthesis.
A NAGK subunit consists of the classical a P a  sandwich fold that is formed by a 
core P sheet of eight parallel strands caught between two layers of three and four a  
helices (Figure 2.3d). The core P sheet spans across the dimer interface to form a 
continuous 16-stranded molecular P sheet. The N-terminal lobe of each subunit serves as 
the NAG binding site, while the ATP binding site is found in the C-terminal lobe. Each 
subunit contains one catalytic center, and while dimer formation is elaborate and formed 
by many interactions involving six highly conserved residues, it is not known to facilitate 
substrate channeling. Rather, its role is purely structural, providing a scaffold for 
anchoring the complex loop system that forms the substrate-binding site in each subunit 
(19).
The classical a P a  sandwich fold is seen in other enzymes important in the 
biosynthesis of other amino acids, nucleotides and important metabolites (Figure 2.4). 
These enzymes form the amino acid kinase family (AAK) and include carbamate kinase 
(CK) (20), the N-terminal domain of aspartokinase (AK) (21), glutamate-5-kinase (G5K) 
(22), and uridylate monophosphate kinase (UMPK) (23). The recently determined 
structure of the bacterial resistance enzyme FomA in S. wedmorensis also has this 
characteristic fold. IPK from THA, MTH and MJ are expected to possess the a P a  
sandwich fold based on sequence alignments with NAGK (Figure 2.5). This chapter
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Figure 2.4. The a P a  sandwich fold is characteristic of enzymes in the amino acid kinase 
(AAK) family. (a) N-acetyl-L-glutamate kinase (NAGK) (1GS5). (b) Carbamate kinase 
(CK) (2WE4). (c) The N-terminal domain of aspartokinase (AK) (2JOX). (d) L- 
glutamate-5-kinase (G5K) (2J5T). (e) Uridine monophosphate kinase (UMPK) (2BMU). 
(f) Fosfomycin kinase (FomA) (3D41).
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Figure 2.5. Sequence alignment of four enzymes of the amino acid kinase family shows 
conservation of catalytic and binding residues. The degree of conservation of residues is 
color-coded, with red signifying highest conservation among the compared sequences. 
Residues marked with (•) are known in E. coli NAGK to perform key organizing and 
transition state stabilizing roles in the phosphoryl transfer reaction, and are also found in 
THA and MTH IPKs and in FomA. Residues marked with (♦ ) are found only in IPKs 
and in FomA. Glycine-rich loops that facilitate phosphoryl transfer are labeled A and B, 
while ATP binding regions are labeled C and D.
presents the first structures of THA and MTH IPKs, as apoenzyme in the case THA IPK 
and in ternary complex with substrates and products for both MTH and THA IPKs. The 
structures that will be presented confirm the structural prediction as well as elucidate the 
key similarities and differences between archaeal IPKs and other enzymes in the AAK 
family.
Experim ental Procedures
Gene amplification and cloning. The THA IPK gene was amplified from genomic 
DNA (ATCC: 25905D) by PCR using PfuUltra II DNA polymerase (Stratagene) and the 
forward and reverse primers 5'-CACCATGATGATACTGAAGATAGG-3' and 5’-  
TCATCTTATCACCGTACCTATGAATG-3', respectively. The forward primer contains 
the sequence CACC, which anneals with the overhang sequence of the topoisomerase- 
charged cloning vector, pET151/D-TOPO (Invitrogen). The double stranded PCR 
product was directionally cloned into the pET151/D-TOPO vector to append an N- 
terminal hexahistidine tag, the V5 epitope, and a TEV protease cleavage sequence 
upstream o f the start codon. The resulting construct was used to transform E. coli DH5a 
cells, which were then grown overnight in LB plates containing ampicillin. Single 
colonies were picked for purification o f plasmids containing the THA IPK gene. 
Plasmids containing the correct insert were used to transform E. coli BL21 (DE3)- 
CodonPlus-RIL cells (Stratagene) for repeatable and high-yield expression. The 
amplification and cloning of the MTH IPK gene is described in reference (24).
Protein expression and purification. Selenomethionine-substituted THA IPK was 
produced in E. coli BL21 (DE3)-CodonPlus-RIL (Stratagene) using the autoinduction
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method (25). A starter culture was grown overnight in PA-0.5G media containing 
chloramphenicol and ampicillin, and then diluted 1000-fold in PASM-5052 media 
containing 25 mg mL-1 selenomethionine, 1x trace metals mix, 100 vitamin B12 and 
17 amino acids (each at 10 mg mL-1) excluding cysteine, tyrosine and methionine. The 
culture was incubated at 37 °C for 8 h followed by incubation at 23 °C until OD600 > 8.0. 
Cells were harvested by centrifugation, resuspended and lysed in binding buffer 
containing 50 mM Na2HPO4, pH 8.0, 150 mM NaCl, 10 mM imidazole and 1 mM P- 
mercaptoethanol. DNAse (1 .^g mL-1) and lysozyme (1 mg mL-1) were added to the cell 
suspension and incubated for 30 min. The cell suspension was sonicated for three min, 
and cell debris was removed by centrifugation (20,000 x g for 25 min at 4 oC). The 
supernatant was heat-treated for 15 min at 50 °C before another centrifugation step. The 
clarified supernatant was incubated at 4 °C with Ni-NTA resin (Qiagen) preequilibrated 
with binding buffer. Bound proteins were eluted with buffer containing 50 mM Na2HPO4, 
pH 8.0, 150 mM NaCl, 250 mM imidazole and 1 mM P-mercaptoethanol. Eluted proteins 
were pooled and the hexahistidine tag and V5 epitope were removed by adding 
recombinant TEV protease at 1 mM with dialysis against a buffer solution containing 
50mM Tris-HCl, 150mM NaCl and 1mM DTT at 4 °C for 24 h. The dialysate was then 
subjected to another round of dialysis using the same buffer without DTT for another 4 h. 
The resulting dialysate was then applied to Ni-NTA and the flow through containing the 
cleaved THA IPK was subjected to a final purification step by gel filtration using 
Superdex 200 (GE Healthcare) equilibrated with 50 mM HEPES pH 7.5, 150 mM NaCl, 
1mM P-mercaptoethanol. Using the extinction coefficient 17,880 M-1 cm-1 at 280 nm 
calculated using the ProtParam tool in the ExPASy Proteomics server (26), THA IPK
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concentration was estimated and protein was concentrated to 0.30 mM for subsequent 
crystallization. Selenomethione incorporation of cleaved THA IPK was confirmed by 
mass spectrometry. Native THA IPK was obtained by growing transformed BL21 (DE3)- 
CodonPlus-RIL cells (Stratagene) in ZY-5052 autoinduction media and purified using the 
same procedure for THA IPK.
The expression and purification of MTH IPK is described in (24). For 
crystallization, the purified protein was concentrated to 5 mg mL-1 in a stabilization 
buffer of 25 mM HEPES, pH 7.5, 75 mM NaCl, 0.5 mM P-mercaptoethanol.
Crystallization. All crystals of THA IPK were grown by the sitting drop vapor 
diffusion method at 21 °C using a mixture consisting of 0.30 mM protein, 1.5 mM 
MgCl2, 1.5 mM IP and 1.5 mM ATP that was prepared and incubated for at least two h 
before crystallization. In all cases the crystals grew to maximum dimensions in about one 
week in drops of a 1:1 mixture of protein and reservoir solutions. Selenomethionine- 
substituted THA IPK crystals complexed with IP and ADP were grown using a solution 
of 0.1 M sodium citrate, pH 5.0, and 15% PEG 6000. Crystals grew to maximum 
dimensions in about one week. The IPK^IP^ATP crystal was grown using native protein 
and a reservoir solution of 0.1M MIB buffer (2:3:3 molar ratio of sodium malonate, 
imidazole and boric acid), pH 7.0 and 25% PEG 1500. The IPK^IPP^ADP crystal was 
obtained using selenomethionine-substituted protein and a reservoir solution of 0.1M 
PCB buffer (2:1:2 molar ratio of sodium propionate, sodium cacodylate and Bis-Tris 
propane) pH 6.0 containing 25% PEG 1500. In this case the substrate included with the 
crystallized protein was converted and preferentially bound as product under the 
crystallization conditions. Crystals of MTH IPK were grown by mixing 2 ^L protein (5
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mg mL-1 MTH IPK, 5 mM MgCl2, 1 mM ATP) with a precipitant solution containing 
12% PEG 6000 and 2M NaCl.
Crystal structure determination. Prior to data collection, all crystals were 
cryoprotected by immersion for 30 s in a modified reservoir solution that contained 30% 
glycerol and cooled by plunging into liquid nitrogen. Diffraction data were collected at 
100 K on a rotating anode source or at beamline 11-1 of the SSRL and processed using 
HKL2000 (27). The THA IPK structure in complex with IP and ADP was determined by 
single wavelength anomalous diffraction (SAD) using PHENIX (28). Model building was 
done using COOT (29). Refinement used REFMAC5 (30) with the final refinement 
cycles performed using PHENIX. This refined model was used to determine all of the 
other structures by molecular replacement using PHASER (31) in the CCP4 suite (32).
The DaliLite server (33) was used to superimpose the C a atoms of two protein 
structures and measure the RMSD between the two. Molprobity (34) was used for 
structure validation. PyMol (35) and the command “Ray” were used to create images of 
the protein structures.
Metal ion requirement. The metal ion dependence of IP kinase was determined by 
the radioactivity assay using IP and [32P] ATP (American Radiolabeled Chemicals) as 
substrates (24). Reaction mixtures contained solutions prepared using 18 MQ deionized 
water, including 100 mM HEPES, pH 7.5, 10 mM P-mercaptoethanol, 0.1% (w/v) BSA, 
400 |^M IP, 400 |^M [32P] ATP and 10 mM of MgCh, MnCh, ZnCh, CuCh, NiCk, CdCh 
or CoCl2  (atomic absorption grade, Alfa Aesar). The reactions were initiated by adding 
purified THA IPK to a final volume of 50 ^L followed by incubation at 37 °C for 10 min. 
Reactions were quenched by adding 113 ^L of methanol/750 mM EDTA (100:13, v/v).
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Samples (6 ^L) of the quenched reaction mixtures were spotted on silica TLC plates and 
developed with CHCl3/pyridine/formic acid/H2O (30:70:16:10, v/v). The TLC plates 
were imaged for 24 h using a storage phosphor imager autoradiography cassette and 
visualized by a Typhoon 8600 variable mode imager.
Results
Gene amplification and cloning. Directional TOPO® Cloning (Invitrogen) was used 
to incorporate the THA IPK gene to the pET151/D-TOPO vector. The previous kinetic 
studies by Chen and Poulter relied on pET28b-based constructs for both THA and MTH 
IPK. While pET28b-MTH IPK yielded well-diffracting crystals that resulted in a native 
diffraction data set to 2.15 A, pET28b-THA IPK yielded highly mosaic crystals with 
overlapping diffraction spots that made data reduction inaccurate. On the other hand, the 
pET151/D-TOPO-THA IPK construct proved to be desirable, eventually leading to 
quality crystals that diffracted to as low as 1.90 A.
Directional TOPO® Cloning is based on the ability of topoisomerase I from 
Vaccinia virus to bind duplex DNA at specific sites and cleave the phosphodiester 
backbone after 5’-CCCTT in one strand. The energy from the broken phosphodiester 
backbone is conserved by the formation of a covalent bond between the 3’ phosphate of 
the cleaved strand and Tyr274 of topoisomerase I. The enzyme-DNA phosphotyrosyl 
bond can be attacked by the 5’ hydroxyl of the original cleaved strand, reversing the 
reaction and releasing topoisomerase. Directional joining of the double-stranded THA 
IPK gene to pET151/D-TOPO is made possible by adding a 5’-CACC sequence to the 
insert, which is complementary to the 3’-GTGG overhang in the cloning vector. The
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overhang in the pET151/D-TOPO vector invades the 5’-end of the THA IPK insert and 
stabilizes it in the correct orientation. The insert was then cloned into the pET151/D- 
TOPO vector and the duplex sequence was verified to be correct.
Protein expression and purification. Constructs of either MTH or THA IPK based 
on the pET28b vector always resulted in overexpressed proteins with greater than 95% 
purity after SDS PAGE, and size exclusion chromatography consistently increased the 
purity to almost 99%. Due to the inability of the pET28b-THA IPK construct to yield 
quality crystals, the pET151/D-TOPO-THA IPK construct was created. Unfortunately, 
even after optimization of purification steps that included heat treatment, overexpressed 
THA IPK coeluted with many cell impurities during SDS PAGE (Figure 2.6a). Cleavage 
of the histidine tag and the V5 epitope by TEV protease followed by another metal ion 
chromatography step diminished the amount of impurities, leading to an enriched THA 
IPK with greater than 95% purity (Figure 2.6b). Size exclusion chromatography using 
Superdex 200 removed the remaining impurities (Figure 2.6c) yielding ultrapure THA 
IPK suitable for crystallization trials. Like MTH IPK, THA IPK is dimeric in solution, as 
shown by size exclusion chromatography using a column calibrated with protein 
standards. For cells grown in the presence of selenomethionine, mass spectrometry 
confirmed the substitution of all 12 methione residues in each THA IPK subunit with 
selenomethionine, making this derivative suitable for structure determination via 
anomalous scattering experiments.
Crystallization and structure determination. We have determined structures of IP 
kinases from two archaeal species, THA and MTH, with crystals obtained under a variety 
of conditions. All crystals were grown in the presence of IP and ATP. Although
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Figure 2.6. Purification of THA IPK prior to crystallization requires three steps. (a) SDS 
PAGE after first Ni affinity chromatography step shows overproduction of THA IPK. (1) 
Molecular weight markers, (2-4) fractions eluted with 250 mM imidazole. (b) Digestion 
of the histidine tag by TEV protease leads to further purification of THA IPK. (5) Flow 
through containing tagless THA IPK, (6) fraction eluted with 250 mM imidazole after 
TEV cleavage. (c) Size exclusion chromatogram showing a large peak for the THA IPK 
dimer.
structures of homologous proteins have been determined and are available in the Protein 
Data Bank (PDB), none of these structures proved suitable for molecular replacement 
even after the removal of nonconserved motifs. Isomorphous replacement using Hg, Sm, 
and Gd crystal soaks also did not yield sufficient phasing power or correct phases for 
structure determination. Thus, the THA IPK structure was determined by single 
wavelength anomalous diffraction (SAD) using crystals of selenomethionine-substituted 
protein grown in 0.1 M citrate buffer, pH 5.0 (Figure 2.7a). Data were collected from the 
Stanford Synchrotron Radiation Lightsource (SSRL) Beam Line 11-1, and a sample 
diffraction image from a selenomethionine derivative crystal with resolution up to 1.90 A 
is shown in Figure 2.7b. Data for multiwavelength anomalous diffraction (MAD) phasing 
were collected after performing a fluorescence scan on a selenomethionine derivative 
crystal to identity the Se peak (0.97644 A) and inflection (0.97934 A) wavelengths, as 
well as a third “remote” wavelength (1.5418 A), at which to collect anomalous data sets 
(Figure 2.7c). Despite the availability of three anomalous data sets, MAD phasing did not 
yield an interpretable electron density map. SAD phasing using the Se peak data set 
located a total of 45 selenium sites that were used to calculate initial phases to 1.90 A. 
The phase estimates were improved by density modification to generate a readily 
interpretable electron density map where almost 70% of the THA IPK structure was 
autobuilt by PHENIX (Figure 2.8a). The rest of the protein structure was built manually 
and wrong connectivities were corrected in COOT. The structure of THA IPK with 
labeled secondary structures is shown in Figure 2.8b (36).
The crystal asymmetric unit of the SAD structure contained two molecules of 
IPK, each of which contained IP and ADP in the active site (Figure 2.9). This
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Figure 2.7. Multi wavelength anomalous diffraction data collection from crystals of 
selenomethionine-substituted THA IPK. (a) Rod-like crystals of THA IPK grown in 0.1 
M citrate buffer, pH 5.0. (b) Sample image showing well-defined diffraction spots up to 
2.0 A. (d) Kramers-Kronig transformation of a fluorescence scan of a selenomethionine 
crystal used to identify the Se peak and inflection wavelengths, as well as a remote 
wavelength, at which to collect diffraction data.
combination of ligands presumably resulted from hydrolysis of ATP that occurred during 
sample preparation and crystallization and may constitute a dead end complex. This 
refined structure was used as a search model in subsequent molecular replacement 
solutions of other IPK crystal forms. Comparison of this IPK^IP^ADP dead end complex 
with other structures that were subsequently solved showed no significant differences in 
tertiary structure and conformation of important active site residues. Thus, in the 
following discussion of the structure of IPKs, reference will be made to more interesting 
and complete structures that contain the substrates IP and ATP, as well as the products 
IPP and ADP, unless otherwise noted.
THA IPK crystals grown in 0.1 M malonate/imidazol e/borate (MIB) buffer, pH 
7.0, contained two molecules of the enzyme in the asymmetric unit (Figure 2.10a). The 
two asymmetric unit molecules were almost identical and both contained IP and ATP in 
the active site, and will be called IPK^IP^ATP (Figure 2.10b and c). An Fo-Fc omit map 
contoured at 1a confirms the identity of these ligands (Figure 2.10d). In addition, THA 
IPK crystals grown in propionate/cacodylate/Bis-Tris (PCB) buffer, pH 6.0 contained 
four molecules in the asymmetric unit (Figure 2.11a) where two molecules contained the 
products IPP and ADP (Figure 2.11b, c, and d) formed during crystallization, while the 
other two contained the substrates, IP and ATP (Figure 2.11e and f). An Fo-Fc omit map 
shows the proper assignment of the products IPP and ADP to the electron density (Figure 
2.11b). The presence of substrate and product complexes in the asymmetric unit is 
reasonable given an equilibrium constant for the reaction, Keq = 6.3, for uncomplexed 
substrates and products (24). A structure for MTH IPK with two molecules in the 
asymmetric was also determined (Figure 2.12a). The asymmetric unit molecules
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Figure 2.8. The tertiary structure of THA IPK contains the classical a P a  sandwich fold 
found in other amino acid kinase enzymes. (a). 2Fo-Fc electron density map showing the 
crystal lattice and a dimeric THA IPK built into the electron density. (b). Ribbon 
representation of THA IPK with labeled secondary structure, where all the elements 
found in the NAGK enzyme are also found in THA IPK.
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Figure 2.9. 2Fo-Fc map of the dead-end complex showing bound substrate IP and product 
ADP. The structure was solved by single wavelength anomalous diffraction and was used 
as a model to solve other structures by molecular replacement. Water molecules in the 
cavity between IP and ADP are shown as red spheres.
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Figure 2.10. 2.0 A crystal structure of the THA IPK substrate complex. (a) The crystal 
asymmetric unit contained two molecules of IPK that form a dimer. (b) 2Fo-Fc map 
showing bound substrates IP and ATP, with active site water molecules shown as red 
spheres. (c) Alternate view of the active site showing the core P-sheet structure of IPK. 
(d) Fo-Fc ligand omit map showing electron density with modeled IP and ATP, indicating 
correct assignment of ligands.
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Figure 2.11. 1.99 A crystal structure of the THA IPK product complex. (a) The crystal 
asymmetric unit contained four molecules. (b) Fo-Fc ligand omit map showing correct 
assignment of bound products, IPP and ADP to the electron density. (c) and (d) Two 
molecules in the crystal asymmetric unit contained bound products, IPP and ADP, shown 
above in two alternate views. (e) and (f) The other two molecules in the crystal 
asymmetric unit contained the substrates, IP and ATP. The presence of both substrates 
and products in the asymmetric unit was reasonable given the equilibrium constant 
between substrates and products, Keq = 6.3. Water molecules are shown as red spheres.
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Figure 2.12. 2.15 A crystal structures of MTH IPK. (a) The crystal asymmetric unit 
contained two molecules of MTH IPK that form a dimer. (b) and (c) 2Fo-Fc electron 
density map showing bound product, ADP and a glycerol molecule that presumably 
displaced IPP during crystal mounting. Water molecules are shown as red spheres.
contained ADP and either glycerol or water molecules in the IP binding site (Figure 
2.12b and c). Glycerol presumably displaced a bound IP molecule when the crystal was 
being prepared for cryogenic data collection. Finally, the structure of the THA IPK 
apoenzyme with six molecules in the asymmetric unit was determined from a crystal 
grown in 2.0 M (NH4)2SO4 (Figure 2.13a). A representative subunit contains two sulfate 
molecules that are each positional mimics of the terminal phosphate of IP and the P 
phosphate of ATP, and molecules of water. The His50 residue was positioned in a 
different conformation than those in other structures (Figure 2.13b). All of the five 
structures were refined to Rfree values of 23-27% against data to 2.0-2.7 A resolution. All 
structures have excellent geometry, with more than 95% of the residues in favored 
Ramachandran regions. Crystallographic and refinement statistics for each structure are 
given in Table 2.1.
All of the crystallized proteins of THA IPK included N-terminal Phe(-1) and 
Thr(0) residues that were the remnants of a TEV protease recognition site. In some cases, 
one or both of these residues were visible in the electron density. Moreover, electron 
density for residues Asp(-3) and Pro(-2), also parts of the TEV protease recognition site, 
were found in the asymmetric unit of the crystal grown in PCB buffer. This asymmetric 
unit was interesting because of the combination of bound substrates and products in the 
molecules mentioned earlier, as well as the significant movement of loops in two 
molecules. Briefly, molecules A, B contained bound products, while molecules C and D 
contained bound substrates. In molecules C and D, the n1-aA  loop was in a 
conformation different than those in molecules A and B (Figure 2.14a), which allowed 
these molecules to make crystal lattice contacts through Tyr17 (Figure 2.14b). This loop
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Figure 2.13. 2.7 A crystal structure of the THA IPK apoenzyme. (a) Six THA IPK 
subunits formed the crystal asymmetric unit, containing water molecules (red spheres) 
and sulfate molecules (sticks). (b) 2Fo-Fc electron density map showing bound sulfate 
molecules that mimic the positions of the IP phosphate group and the P-phosphate group 
of ATP. No clear electron density was observed for Lys14 presumably due to multiple 
conformations arising from the absence of ATP.
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Table 2.1. Data collection and refinement statistics. Statistics for highest resolution shell 
are in parentheses. aRsym = 2 |I - <I>|/ZI, where I is the observed intensity, and <I> is the 
average intensity of multiple observations of symmetry-related reflections. bRfactor = 2 
||Fobs| - |Fcalc||/Shkl|Fobs|, where Fobs and Fcalc are the observed and calculated structure 
factors, respectively.
IPK«IP«ATP IPK«IPP«ADP M TH IPK
Space Group C2 C2 C2
Cell Dimensions a = 124.31 
b = 44.48 
c = 91.76 
P = 109.45
a = 187.10 
b = 42.79 
c = 134.90 
P = 113.19
a = 119.67 
b = 96.36 
c = 72.43 
P = 120.59
Molecules/ asu 2 4 2
Wavelength (A) 1.54 0.97887 1.54
Resolution range 
(A) (outer shell)
29.30 -  2.00 
(2.07 -  2.00)
50.00 -  1.99 
(2.06 -  1.99)
30.00 -  2.15 




31, 495 68, 827 38, 177
Rsyma (%) 7.5 (4.5) 6.20 (23.4) 9.1 (45.4)
Completeness 98.0 (95.2) 94.6 (80.9) 92.3 (66.2)
Resolution range 29.30 -  2.00 38.29 -  1.99 30.00 -  2.15
Rfactor b(work/test) 
(%)
17.6/23.0 19.2/23.4 20.7/ 26.0




Most favored (%) 98.70 97.81 94.02
Allowed (%) 1.30 2.19 5.92
Disallowed (%) 0.00 0.00 0.06
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Figure 2.14. 2Fo-Fc electron density maps of THA IPK showing alternate conformations 
for the n1-aA  loop containing Lys14, shown in blue cartoon. (a) In the first 
conformation, Tyr17 is oriented towards the long aC  helix and Lys14 is in a transition 
state stabilizing conformation. (b) In the second conformation, the n1-aA  loop is turned 
away from the aC  helix and toward the neighboring subunit. The side chain of Lys14 is 
stabilized in a hydrophic cleft in the neighboring subunit and forces Lys14 away from the 
phosphorylation reaction site.
movement resulted in a significant shift in the side chain position of Lys14, an invariant 
residue in IPKs and in FomA with direct involvement in catalysis to be discussed later. 
Moreover, in molecules C and D, an alternate conformation was found for another 
conserved catalytic residue, His50 (Figure 2.15). An active site water molecule found in 
AAK enzymes was found only in molecules A, C and D. The unique characteristics of 
these asymmetric unit molecules allowed us to choose molecule A as the best structure 
that represents the THA IPK product complex (IPK^IPP^ADP).
Discussion
Fold and quaternary structure o f IPK. IPK belongs to the amino acid kinase 
(AAK) family of enzymes that also includes NAGK, the AK N-terminal domain, G5K, 
CK, UMPK and FomA (37, 38) (Figure 2.3). This family is characterized by the open 
a P a  sandwich fold first observed in E. faecalis CK, and catalyzes the transfer of a 
phosphoryl group from a nucleotide to a small molecule acceptor. Depending on the 
functional group that is phosphorylated, this family can be divided into two subdivisions 
(Figure 2.16). Enzymes in the “carboxylate” subdivision catalyze the transfer of a 
phosphoryl group to a carboxylate or carbamate group (NAGK, CK, G5K and AK), while 
those in the “phosphate” subdivision transfer a phosphoryl group to a phosphate or 
phosphonate (UMPK, FomA, IPK) (36, 39). THA IPK is structurally most similar to 
FomA, where the backbone RMSD is 2.6 A on 224 residues. Overlap of THA IPK with 
FomA (Figure 2.17a) and NAGK (2.17b) also aligns their respective substrates and most 
of their active site residues, suggesting similar catalytic mechanisms. As expected, MTH 
IPK shares high structural similarity with THA IPK with RMSD of 1.9 A over 223 C a
70
71
Figure 2.15. A 2Fo-Fc map showing an alternate conformation found for His50 in one of 
the subunits in the crystal asymmetric unit containing both the IPK^IPP^ADP and 
IPK^IP^ATP complexes.
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Figure 2.16. Reactions catalyzed by members of the amino acid kinase family of 
enzymes. Carbamate kinase (CK), aspartokinase (AK), L-glutamate-5-kinase (G5K), and 
N-acetyl-L-glutamate kinase (NAGK) whose substrates contain either a carboxylate or 
carbamate group, belong to the carboxylate subdivision. Fosfomycin kinase (FomA), 
uridine monophosphate kinase (UMPK) and isopentenyl phosphate kinase (IPK) 
phosphorylate substrates with either a phosphate or phosphonate group and belong to the 
phosphate subdivision in the AAK family. Enzymes in the family have highly divergent 
sequences, with IPK and FomA having the highest sequence identity at 20-25%.
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Figure 2.17. Stereoviews of the superimposed structures of THA IPK, FomA and 
NAGK. (a) Superposition of THA IPK and FomA. The top panel shows good overlap of 
the overall tertiary structures of the two enzymes as well as the location of their 
substrates. THA IPK is colored green and FomA is colored blue. The substrates of THA 
IPK (IP and ATP) are colored black while those of FomA (fosfomycin and the inert ATP 
analog, ANP or AMPPNP) are colored white. Conserved residues that bind the respective 
substrates of the two enzymes are shown as sticks. (b) Stereoviews of the superimposed 
structures of THA IPK (green) and NAGK (red). The substrates IP and ATP of THA IPK 
(black) and those of NAGK (NAG and ANP, grey) superimpose well (top panel), and the 
residues that bind ATP in both enzymes are conserved. Residues that bind the phosphoryl 
acceptor (IP and NAG) differ between the two enzymes. The amphipathic molecule IP is 
bound on the phosphate end with polar residues, while its aliphatic C5 tail is bound by 
hydrophobic residues. NAG, which contains two carboxylate groups and an acetyl group, 






atoms, although sequence identity is only 32% (Figure 2.18a and b). These structural 
comparisons confirm the correct assignment of THA and MTH IPKs to the AAK family 
of enzymes.
The THA IPK structure contains an N-terminal domain (residues 1-155) that 
binds IP and a C-terminal domain (residues 156-245) that binds ATP. Each molecule of 
THA IPK consists of 16 P-strands, eight a-helices and two 310 helices interconnected by 
loops and turns (Figure 2.19a). The open a P a  sandwich fold formed by these secondary 
structures is highly similar to that of NAGK: the same structural elements form the 
central P-sheet core (P5, P8, P2, P1, P11, P15, P16, P 14) and the two flanking layers of 
a-helices (aC, aA , aH  on one side and aD ,aE , aG , aF  on the other). Three P-hairpin 
turns reside in the N-terminal domain, two of which form the surrounding walls of the 
aliphatic tail of IP (P3-P4, P9-P10) and another forming one side of the IP binding pocket 
(P6-P7). The P3-P4 hairpin turn of THA IPK is shorter than that of NAGK but is in the 
same closed conformation that allows it to cap the IP binding site and shield its 
hydrophobic surroundings from solvent molecules (19). The remaining P12-P13 hairpin 
turn resides in the C-terminal domain and hovers above the purine ring of ATP. This P 
hairpin is found within the segment that connects the core P-sheet strands P11 and P14 
and is longer than the corresponding segment in NAGK. The longest helix in THA IPK, 
aC , aligns well with aC  in NAGK, but is one turn longer (Figure 2.19b). The segment 
between P 14 and aG  (residues 189-201) in the THA IPK structure is disordered in all 
molecules in the asymmetric unit, as evidenced by uninterpretable electron density. This 
segment contains the helix, aF  and the aF -aG  junction loop that form one side of the 
ATP binding site (Figure 2.19b). The corresponding segment in MTH IPK is missing
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Figure 2.18. Superposition of THA IPK (green) and MTH IPK (deep teal) complexes. 
Catalytic residues, including the lysine triangle, the conserved histidine and the 
organizing aspartic acid side chain are shown in sticks. Both structures are missing the 
aF  helix and the loop connecting the aF  and G helices, which contain the conserved 
DVTGG sequence that are known to bind both substrate and nucleotide in FomA. The 
aC  helix of MTH IPK is one turn longer than that of THA IPK.
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Figure 2.19. Tertiary structure of THA IPK compared with that of NAGK. (a) THA IPK 
with substrates IP and ATP in the active site, showing secondary structures that bind 
these ligands. (b). Superposition of THA IPK (green) and NAGK (red) structures, 
showing the missing aF  helix and the loop that connects it to the aG  helix. The aC  helix 
of THA IPK is one turn longer than that of NAGK.
(204-218), as is also seen in one molecule of G5K (2J5T) (22), suggesting that the 
flexibility of these secondary structures might be important for the binding and release of 
ATP.
The THA and MTH IPKs are dimeric in the crystal, consistent with the observed 
oligomerization state during gel filtration chromatography (Figure 2.20a). The dyadic 
axis is perpendicular to the core P-sheet that runs across the dimer (16 P-sheets, 8 per 
subunit). As in all enzymes of this family that catalyze phosphoryl transfer, each active 
center is confined to a single subunit. However, dimer formation may be structurally 
significant since N-terminal domain loops surrounding the active site are anchored to the 
other subunit of the dimer (19). Analysis of the dimerization surface of THA IPK using 
the EBI PISA (40) server resulted in a complexation significance score of 0.797, 
corresponding to a tight dimer that buries a total of 3275 A2 of solvent accessible area 
between the two monomers. The compactness arises from a total of nine hydrogen 
bonding interactions between residues in the long interfacial aC  helices of both subunits 
and between the aD  helix of one subunit and the P4, P6, and P9 strands and the r(2 helix 
of the other. Eight electrostatic interactions between the aC  helices of the two subunits 
and between the P6 strand of one subunit and the P7 strand of the other further stabilize 
the dimer. Finally, hydrophobic interactions mediated by residues in the aC , aD  and n3 
helices, and the P4, P5, P6, P9 and P10 strands further bind the two molecules. Table 2.2 
a and b list all electrostatic, hydrophobic and hydrogen bonding interactions that stabilize 
the dimer.
Although essentially the same secondary structures are used by the AAK enzymes 
in dimerization, different quaternary architectures are generated by changing the angle
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Figure 2.20. THA IPK and MTH IPK dimers. (a) The dimer of THA IPK showing 
secondary structures containing residues that interact at the dimerization surface. The 
same secondary structures form the dimeric interface in MTH. The dyadic axis is 
depicted by (♦). The unique dimeric architectures of THA and MTH IPKs are generated 
by the crossover angle between the aC  helices of each subunit. In both enzymes, this 
angle is 220°.
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Table 2.2 Noncovalent interactions on the dimerization surface of THA IPK (a) and 
MTH IPK (b). Data on this table were obtained from analyses of the crystal structures 
using the EBI PISA server.
a. THA IPK
Hydrogen bonds
Chain B Distance (A) Chain A
Y117 (OH) 2.89 Y70 (OH)
S97 (OG) 3.01 E78 (OE1)
R75 (NH2) 2.86 D86 (OD1)
S71 (OG) 2.64 P95 (O)
Y117 ()H) 2.68 S101 (O)
R104 (NH2) 3.82 T112 (OG1)
Y70 (OH) 2.77 Y117 (OH)
R116 (NH2) 2.74 I132 (O)
R94 (NH1) 3.65 Y138 (OH)
E78 (OE1) 3.57 S97 (OG)
D86 (OD1) 2.65 R75 (NH2)
P95 (O) 2.89 S71 (OG)
S101 (O) 2.60 Y117 (OH)
Y105 (O) 2.86 R116 (NH1)
A120 (O) 3.10 K62 (NZ)
I132 (O) 3.14 R116 (NH2)
Y138 (OH) 3.54 R94 (NH1)
Salt bridges
Chain B Distance (A) Chain A
R75 (NH2) 2.86 D86 (OD1)
R75 (NE) 3.88 D86 (OD1)
R104 (NE) 3.33 D110 (OD2)
R104 (NH1) 3.78 D110 (OD2)
D86 (OD1) 2.65 R75 (NH2)
D86 (OD1) 3.76 R75 (NE)
D110 (OD1) 3.90 R104 (NE)





Chain B Distance (A) Chain A
S104 (OG) 3.63 Q81 (OE1)
K85 (NZ) 2.80 N88 (OD1)
N82 (ND2) 3.26 S89 (O)
K85 (NZ) 3.74 C92 (SG)
N82 (ND2) 2.89 D93 (OD1)
K86 (NZ) 2.84 D93 (OD1)
Q106 (NE2) 3.11 S104 (OG)
Y129 (OH) 2.69 S108 (O)
R112 (NH2) 3.20 S124 (O)
R112 (NH2) 3.78 S124 (OG)
R112 (NH2) 3.14 S128 (OG)
R112 (NH2) 2.90 S128 (OG)
R74 (NH1) 3.65 G133 (O)
Q81 (OE1) 3.62 S104 (OG)
N88 (OD1) 2.66 K85 (NZ)
S89 (O) 3.28 N82 (ND2)
C92 (SG) 3.72 K85 (NZ)
D93 (OD1) 2.71 N82 (ND2)
D93 (OD1) 2.88 K86 (NZ)
S104 (OG) 3.46 Q106 (NE2)
S108 (O) 2.68 Y129 (OH)
S124 (OG) 3.34 R112 (NH2)
S128 (OG) 3.28 R112 (NH2)
S128 (OG) 3.06 R112 (NH2)
E132 (O) 3.00 R74 (NE)
E132 (OE2) 3.31 K151 (NZ)
G133 (O) 3.73 R74 (NH1)
Salt bridges
Chain B Distance (A) Chain A
K86 (NZ) 2.84 D93 (OD1)
K86 (NZ) 3.51 D93 (OD1)
K151 (NZ) 3.27 E132 (OE2)
D93 (OD1) 2.88 K86 (NZ)
D93 (OD2) 3.05 K86 (NZ)
E132 (OE1) 3.20 K151 (NZ)
E132 (OE2) 3.31 K151 (NZ)
between the long interfacial helices aC  of the dimer subunits (41). In the case of THA 
IPK, the crossover point of these helices is found on the fifth turn from the N-terminus, 
and the rotation angle around an axis that penetrates the inter-subunit interface 
perpendicularly at this point is ~220° (Figure 2.20b). In MTH IPK, the crossover point 
shifts to the sixth turn from the N-terminus while the rotation angle remains at ~220° 
(Figure 2.20b). In NAGK and CK the crossover points in aC  occur in the third turn, and 
shifts to the fifth turn in G5K, while the rotation angles are 110° in both NAGK and CK 
and 260° in G5K (41).
The active site. The THA IPK structures presented here are the first to show the 
molecular details of binding IP and IPP molecules by an enzyme (Figure 2.21a and b). 
Many characteristics of AAK enzymes have been described previously in the discussion 
of the NAGK structure, and several of these traits are conserved in both THA and MTH 
IPKs. Briefly, the IP (IPP) binding pocket is located in the N-terminal domain formed by 
the P2-aB  loop, the aB  helix, the P3-P4 hairpin, the N-terminus of the aC  helix, the 
P8-P9 loop, the P9-P10 hairpin turn, and the P10-aE  loop. The aB  helix contributes to 
binding IP (IPP) through the orientation of the positive end of the helix dipole and the 
hydrogen bonding and electrostatic interactions made by the charged His50 residue. In 
the FomA structure, the aB  helix is ordered in the presence of fosfomycin and disordered 
in its absence (Figure 2.21c) (37). Comparison of AAK enzyme structures revealed that 
only the enzymes in the “phosphate” subdivision (UMPK, FomA and IPK) align their 
respective aB  helices. Moreover, an aligning residue at the His50 position is found 
exclusively in these enzymes, including UMPK (42) (Figure 2.21d).
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Figure 2.21. Comparison of the substrate binding sites of THA IPK, FomA and UMPK.
(a) and (b) The IP and IPP binding sites with important binding and orienting residues 
shown as sticks. Water molecules (W) are shown as red spheres. The water molecule in 
the IPK^IPP^ADP complex has six potential hydrogen bonding interactions. 
Hydrophobic residues bind the C5 tail of both IP and IPP. The phosphate groups of IP 
and IPP are bound by His50, Ser142, the amino group of Gly45, and a conserved water 
molecule. This water bridges the phosphate group of IP to Asp144 via hydrogen bonding. 
His50 binds the P-phosphate of IPP. This movement from the terminal phosphate of IP to 
the P-phosphate of IPP is one of the few coordinate shifts observed in the IPK^IPP^ADP 
complex. Tyr127 and Met77, found immediately below the aliphatic tail of IP, enhance 
the hydrophobicity of the IP binding site and are absent in the active site of FomA (c) 
His58 of FomA interacts with the phosphonate group of fosfomycin via a bridging water 
molecule. Ser148, Ser149 and Thr210 orient the phosphonate group of fosfomycin for 
nucleophilic attack. (d) Superposition of the aB  helices of THA IPK and UMPK, 
showing the alignment of these secondary structures. Arg62 of UMPK corresponds to 
His50 of THA IPK.
His50 in IPK^IP^ATP poises IP for nucleophilic attack on PY of ATP by hydrogen 
bonding with a nonbridging oxygen atom in the phosphate of IP. In the IPK^IPP^ADP 
structure, this residue moves slightly to make a hydrogen bond with a nonbridging 
oxygen atom in the IPP terminal phosphate (Figure 2.21a and b), facilitating the reverse 
reaction. In fact, in comparing IPK^IP^ATP and IPK^IPP^ADP (RMSD 0.4 A), the 
slight change in the position of His50 to hydrogen bond with the terminal phosphate of 
the product is one of the very few coordinate shifts that were observed. In FomA, His58 
positions fosfomycin for nucleophilic attack on the phosphate donor through hydrogen 
bonding with an intervening water molecule (37) (Figure 2.21c). The corresponding 
residue in E. coli UMPK, Arg62, hydrogen bonds with the terminal phosphates of both 
substrate and product and stabilize PY of ATP through electrostatic interactions (42). 
These observations together with the invariance of this histidine residue in putative IPK 
homologues (24, See Supporting Information), the apparent pKa of 6.5 for THA IPK (6.8 
for MTH IPK) from pH dependence studies (24), suggest that this His50 may perform 
direct catalytic roles similar to those proposed for Arg62 in UMPK, besides being a 
signature trait of IPKs (42). Independent experiments performed by Dellas and Noel 
showed that the corresponding residue in MJ IPK, His60 plays an important role in both 
substrate and product sequestration (39). Isosteric mutations on His60 of MJ IPK in 
which the N s1 and N s2 atoms were mimicked through His60Asn and His60Gln 
mutations, respectively, showed that the protonated N s2 nitrogen atom accomplishes the 
said role by donating a hydrogen bond to a nonbridging O atom of the terminal phosphate 
group of either IP or IPP. The His60Gln mutant had a KMIP of 34.5 ^.M compared to 4.30 
^.M for the wild-type MJ IPK, suggesting that His60 is important for ground state
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binding. The additional flexibility of a Gln residue relative to His may hinder its ability to 
bind IP as effectively as wild-type IPK. Moreover, the kcat/KM value for the His60Gln 
mutant was more than 300 times lower than that of the wild-type IPK, suggesting that the 
added charge and lowered conformational stability of His60 are important for the 
stabilization of the highly negatively charged transition state during phosphoryl transfer. 
His60Ala and His60Asn mutants of MJ IPK were both inactive (39).
The specificity of IPK arises from hydrophobic residues that cradle the aliphatic 
portion of IP and a constellation of conserved residues that hydrogen bond with its 
phosphate moiety (Figure 2.21a). Residues Tyr70, Met77 and Val73 (aC  N-terminus), 
Val130 and Ile140 (P9-P10 hairpin) and Ala53 (aB  C-terminus) and Tyr127 (P8-P9 loop) 
all form the hydrophobic pocket for the apolar tail of IP. In addition, Leu58 and Pro59 of 
the P3-P4 hairpin enhance the hydrophobic surroundings by capping the IP binding 
pocket. Notably, the P3-P4 hairpin is found only in the structures of NAGK and IPK. 
This motif is in the closed conformation in substrate-bound NAGK structures (X) as in 
the IPK^IP^ATP and IPK^IPP^ADP structures. The side chains of some, if  not all, of 
these hydrophobic residues may give rise to the chain length specificity of IPK. Geranyl 
phosphate, which is one isoprene unit longer than IP, is a poor substrate for IPK, 
indicating that the IP binding site cannot easily accommodate a C10 isoprenoid chain (24). 
Thus, the mutation of the residues in the IP binding site may expand this space and 
accommodate different conformations of longer chain isoprenoids or other bulkier 
substrates.
The phosphate moiety of IP is recognized in the active site by structural motifs 
that are well conserved in the AAK family. In IPK^IP^ATP, the three nonbridging
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oxygen atoms of IP make hydrogen bonding interactions with the Ns2 of His50, the N 
atom of Gly45 in the P2-aB loop, and Asp144 through a bound water molecule (Figure 
2.21a). This water molecule is found in the holoenzyme structures of E. coli NAGK (pdb 
ID 1GS5), P. furiosis UMPK (pdb ID 2BMU), E. coli UMPK (pdb ID 2BNE) and FomA 
(pdb ID 3D41). A water molecule in a similar position is present in IPK^IPP^ADP 
(Figure 2.21b). The P2-aB loop, which contains Gly45, is one of the conserved glycine- 
rich loops in the AAK family and is thought to stabilize the transition state intermediate 
and the phosphorylated product of these enzymes (37, 43). In IPK^IPP^ADP, Gly45 of 
this loop makes a hydrogen bond with the Pa-Pp bridging oxygen atom of IPP. The other 
glycine-rich loop, P1-n1, contains Gly8 that stabilizes IPP by making a hydrogen bond 
with a nonbridging oxygen atom of its terminal phosphate (Figure 2.21b).
The P10-aE  loop completes the structural elements involved in binding the polar 
end of IP. This loop contains Ser142, which is conserved in the “phosphate” subdivision 
(Thr120 in P. furiosis UMPK, Ser149 in FomA) (23, 37) and makes a hydrogen bond 
with the terminal phosphate of the substrates. In IPK^IP^ATP and IPK^IPP^ADP, the 
orientation of the side chain hydroxyl group of Ser142 does not allow a hydrogen bond 
with substrates or products (Figure 2.21a and b). However, an alternate rotamer could 
provide hydrogen bond stabilization as the substrates moved to the transition state. The 
positive end of the helix dipole of aE, initiated by the P10-aE loop, may further stabilize 
the polar head of the IP molecule as well as the negatively-charged transition state 
intermediate, as in other structures of AAK enzymes.
Thus, the specificity of IPK towards IP arises from a combination of hydrophobic 
interactions with the hydrocarbon tail and hydrogen bonding and electrostatic interactions
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with the phosphate headgroup to match the amphiphatic character of IP. This 
differentiates the IPK active site from other enzymes in the family whose substrates do 
not have this intrinsic amphiphathicity, such as that of NAGK whose active site is laden 
with both polar and charged residues that interact with the acetyl and carboxyl groups of 
NAG (36) (Figure 2.17b).
The location of the ATP binding site in both THA and MTH IPKs superimposes 
well with those of NAGK and other AAK enzymes. Conserved amino acid residues in 
these enzymes, which have previously been shown to form hydrogen bonding, 
electrostatic and hydrophobic interactions with the purine ring, sugar and polyphosphate 
moieties of ATP, are also found in IPK. For instance, the NAGK residues Met214 (purine 
stacking), Asp181 (ribose 3’-OH binding), Asp162 (polyphosphate positioning) and Lys8 
(phosphate hydrogen bonding) are also conserved in THA IPK as Ile202, Asp 164, 
Asp144 and Lys5, respectively (19, 36) (Figure 2.17b). In MTH IPK, the corresponding 
residues are Met220, Asp178, Asp158 and Lys5 (Figure 2.22). Other ATP-binding 
residues in THA IPK that superimpose with similar ATP-binding residues in NAGK are 
shown in (Figure 2.17b). The P 1-n 1 glycine-rich loop that contains Gly8 engages the Pp 
and PY of ATP in IPK^IP^ATP through hydrogen bonding (Figure 2.21a). These 
interactions by the conserved Gly8 with the phosphate groups ATP (and with the terminal 
phosphate of IPP, as described earlier) are seen for the corresponding residue in other 
enzymes and reflect a role in phosphoryl transfer (42, 43). Residues Asp172 and Lys174 
form hydrogen bonds with the 2 ’- and 3’-OH groups of ATP, respectively. Asp172 and 
its corresponding residues in other AAK enzymes may control selectivity for ATP over 
2’-deoxy-ATP (dATP). Finally, a hydrogen bond with the side chain carboxylate of
88
89
Figure 2.22. The nucleotide binding site of MTH IPK contains residues that are 
conserved in THA IPK, NAGK and other amino acid kinase family enzymes.
Asp164 completes an intricate network of interactions that secure this end of ATP, thus 
positioning the polyphosphate end for nucleophilic attack by IP (Figure 2.23).
As stated earlier, aF  and the loop that connects it to aG  were not modeled in our 
IPK structures. These secondary structures contain Phe191, analogous to Trp 202 in 
FomA, which stacks on the adenine ring, and the conserved DVTGG sequence that 
makes important binding interactions with the nucleotide, as seen in other AAK enzymes. 
We suspect that these interactions are largely conserved in IPK, although a more 
complete IPK structure would be necessary to unequivocally establish the nature of these 
interactions. The flexibility and location of these absent secondary structures suggest a 
role in nucleotide sequestration and release.
The IPK^IP^ATP structure was obtained without resorting to a substitution of the 
Pp-Py bridging oxygen atom that would prevent phosphoryl transfer. In addition, 
phosphoryl transfer between added substrates during the crystallization experiments 
provided IPK^IPP^ADP. These two structures, providing snapshots of the IPK enzyme 
before and after catalysis, suggest an important role for Lys14 in stabilizing the transition 
state (Figure 2.10b and Figure 2.11c). This residue is also conserved in FomA and 
homologs of IPK (24, See Supporting Information). This transition state-stabilizing role 
of Lys14 in THA IPK was confirmed by kinetic studies on a Lys14Ala mutant of THA 
IPK. This mutant has a KMIP of 3.4 ^M similar to that for wild-type IPK, suggesting that
ATPLys14 does not directly interact with the substrate IP. On the other hand, KM for the 
Lys14Ala mutant is almost twice that of wild-type THA IPK, while its kcat is 460-fold 
lower than wild type (Figure 2.24). These support the putative roles of Lys14 inferred 
from the crystal structure of THA IPK, in which it makes hydrogen bonding interactions
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Figure 2.23. The ATP binding site of THA IPK showing residues that participate in 
hydrogen bonding and hydrophobic interactions. Hydrogen bonds are shown as blue 
dashed lines. The Mg2+ ion is not found in THA IPK structures, but are presumed to 
coordinate three nonbridging oxygen atoms of the ATP phosphate moiety.
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W ild-type IPK Lys14Ala IPK
kcat (s ) 8.0 (± 0.2) 1.8 (± 0.04) x 10-2
K j P (mM) 4.4 (± 0.5) 3.2 (± 0.5)
cak t K p M-
1 s- 1.8 x 106 5.5 x 103
KmATP (mM) 6.0 (± 0.5) 10.5 (± 0.8)
Kd (mM) 4.6 (± 1.5) 3.8 (± 0.2)
Figure 2.24. Michaelis Menten kinetics of the Lys14Ala mutant of THA IPK. This 
mutation showed that Lys14 is important for transition state stabilization.
to bind the phosphate moiety of ATP as well as help stabilize the highly negatively 
charged transition state through its positive charge.
An associative mechanism of phosphoryl transfer was proposed for NAGK as 
well as for its closest homolog, FomA, Structural evidences for an associated mechanism 
were obtained from structures of the NAGK enzyme containing the transition state mimic 
AlF4-, and in the case of FomA, in complex with fosfomycin vanadate and MgADP (38, 
43). The similarity of the overall fold and the superposition of the substrate and 
nucleotide binding sites of THA and MTH IPKs with these enzymes suggest a similar 
mechanism for IPK (Figure 2.25). In IPK^IP^ATP, a nucleophilic oxygen atom of the 
phosphate group in IP is 2.9 A from the electrophilic PY phosphate atom in ATP, and is 
poised for attack. The angle formed by the nucleophilic oxygen atom of fosfomycin, the 
electrophilic phosphorous of the y-phosphate of ATP and the bridging oxygen atom of the 
P- and y-phosphates of ATP is 157.8°. In the modeled FomAfosfomycin^MgATP 
complex, this angle is 157.9° (38). The products in IPK^IPP^ADP are likewise poised for 
the reverse reaction, where the nucleophilic oxygen atom in Pp of ADP is 2.3 A from the 
electrophilic Pp phosphate atom of IPP, with an angle of attack of 167.9°. As in NAGK, 
the conserved glycine rich loops P 1-n 1 and P2-aB of THA IPK, the positive helix 
dipoles of aB  and aE, and the positive charges of Lys5 and Lys205 (which are 
positioned by Asp144 towards the polyphosphates by hydrogen bonding), create an 
environment for stabilizing the negatively charged transition state. It is understood that 
the concentration of these positive charges at the site of transition indicates an associative 
mechanism for the IPK-catalyzed reaction, which is expected to have a pentacoordinate 
transition state with a charge of -3. In contrast, a dissociative mechanism will have a
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Figure 2.25. An associative mechanism is proposed for the IPK-catalyzed 
phosphorylation reaction.
metaphosphate transition state with a charge of -1, which will be overcompensated for by 
the surrounding residues.
2+A divalent metal ion, Mg , further contributes to stabilization by the same 
mechanism in addition to its orientational effect on the ATP polyphosphate. In 
IPK^IP^ATP and IPK^IPP^ADP, a Mg2+ ion could not be assigned to the electron 
density that superimposes onto the Mg2+ atom in the structure of NAGK. Instead, a water 
molecule is assigned to this density since the distance of the centroid of the sphere to the 
relevant polyphosphate oxygen atoms is more consistent with hydrogen bonding than
with metal coordination. Nevertheless, product turnover assays using radioactive y-[32P]
2+ATP and Mg confirmed the divalent metal ion dependence of IPK, a well-established
2+characteristic of kinases (44) (Figure 2.26a). Thus, Mg is very likely located in the 
same position as the water molecule seen in the crystal structure, based on superposition
with the NAGK complex and the recently determined ternary complex of FomA with
2+fosfomycin and MgATP. The coordination sphere of this Mg maybe completed by the 
three non-bridging O atoms of ATP and three nearby water molecules, as seen in the 
FomAfosfomycin^MgATP complex (38). In the structures of THA IPK solved, at least 
one molecule of water is missing from a complete coordination sphere, while the 
triphosphate moiety of ATP is in a slightly different conformation that allows one 
bridging O atom to form a coordinate bond with the divalent metal. It is also possible that
the entire enzyme contracts to bring the carboxylate group of Asp 150 closer to the
2+divalent metal, thus completing the Mg coordination sphere. More THA IPK structures 
are necessary to confirm these hypotheses. Of the seven structures of FomA deposited in 
the PDB, only four contained Mg2+ in the active site, namely the complexes with
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Figure 2.26. Autoradiography assay showing divalent metal ion dependence of the IPK-
catalyzed phosphorylation reaction. (a) Mg2+ is required for IPK activity. (1) Mg2+
present, (2) Mg2+ not present, (3) Mg2+ present with ten-fold concentration of EDTA, (4) 
2+ 2+Mg not present with ten-fold concentration of EDTA, (5) Mg present, IPK not present,
(6) [14C] IPP control, (7) y-[32P] ATP control. (b) IPK is active in the presence of other
divalent metals. (1) Mg2+, (2) Mn2+, (3) Zn2+, (4) Cu2+, (5) Ni2+, (6) Cd2+, (7) Co2+, (8) no
divalent metal present, (9) [14C] IPP control, (10) y-[32P] ATP control.
MgATP, fosfomycin vanadate and MgADP, fosfomycin monophosphate and MgADP, 
and fosfomycin and MgAMPPNP (37, 38). The complexes with the vanadate derivative
and the inert ATP analogue are the most ordered among the crystal structures, indicating
2+a correlation between the presence of Mg in the metal site and the ordering of flexible 
loops. Finally, IPK was also active in the presence of Mn2+, Zn2+, Ni2+, Cd2+, and Co2+ 
(Figure 2.26b).
In IPK^IP^ATP, Lys14 is located within hydrogen bonding distance of the non­
bridging oxygen atoms of Pa (3.0 A) and PY (2.8 A) and the Pp-PY bridging oxygen atom 
(3.1 A) in ATP. In IPK^IPP^ADP, Lys14 makes a hydrogen bond with a nonbridging 
oxygen atom of Pp (2.7 A) in IPP and the nonbridging oxygen atoms of Pa (2.7 A) and Pp 
(3.0 A) of ADP. A corresponding residue, Lys18, is found in the 
FomA^Fom^MgAMPPNP complex (37). In this structure, Lys18 only forms a hydrogen 
bond with a PY oxygen atom in AMPPNP, which in turn, is not properly oriented for 
nucleophilic attack by fosfomycin. The relative positions of IP and ATP in THA IPK are 
consistent with phosphoryl transfer. Thus, in THA IPK Lys5, Lys14 and Lys205 form a 
lysine triangle surrounding the phosphate residues in the substrates of IPKs (Figure 2.27). 
This lysine triangle was also observed in the FomA^Fom^ATP and 
FomA^FomVO3^ MgADP complexes. Interestingly, the FomA^FomPO4^ MgADP 
complex, which is analogous to the IPK^IPP^ADP complex, does not possess an ordered 
lysine triangle and has been interpreted as an enzyme product complex in the act of 
preparing for product release (38). Thus, the IPK^IPP^ADP complex may approximate a 
step in the IPK-catalyzed reaction before the one represented by the 
FomA^FomPO4^ MgADP complex, wherein the products IPP and ADP are bound in the
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Figure 2.27. The lysine triangle is conserved in IPKs and in FomA. In THA IPK, Lys14 
hydrogen bonds with the phosphate moiety of ATP, and forms a triad with Lys5 and 
Lys205. The residue Asp144 organizes the latter two lysine residues through hydrogen 
binding interactions. Lys5 and Lys205 each can donate a hydrogen bond to the P- 
phosphate of ATP. With the position of Lys14, it is presumed to stabilize the transition 
state during phosphoryl transfer together with Lys5 and Lys205 through neutralization of 
the negatively charged transition state.
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active site just before the movement of the n1-aA  loop that contains Lys14, in order to 
release IPP.
Along with His50, Lys14 is a conserved feature of the IPKs. These residues may 
have evolved to preferentially stabilize transition states that contain more negative charge 
than those formed during phosphoryl transfers involving carboxylated and carbamated 
substrates, thus giving rise to IP kinases. The conservation of these traits in FomA along 
with other key catalytic residues seen in IPK is also consistent with the acquisition of 
antibiotic resistance toward fosfomycin in Streptomyces by a lateral gene transfer of an 
ancestral IPK gene from Archaea. Chapter 3 presents biochemical and computational 
studies that elucidate this possible evolutionary relationship between archaeal IPK and 
bacterial FomA.
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CHAPTER 3
THE STREPTOMYCES-PRODUCED ANTIBIOTIC FOSFOMYCIN IS A 
PROMISCUOUS SUBSTRATE FOR ISOPENTENYL 
PHOSPHATE KINASE
Introduction
Modern enzymes are commonly understood to be highly specific towards the 
substrates and chemical transformations that they catalyze. This selectivity underlies 
catalysis in biology. Moreover, in a living cell where the chemical structures of 
metabolites are highly redundant and where cross wiring of metabolic pathways exists, 
enzyme selectivity prevents the conversion of unintended substrates that wastes cellular 
energy or has other deleterious effects on the organism (1). In contrast, primordial 
enzymes likely possessed substrate ambiguity (the ability to recognize a variety of 
molecules) and catalytic promiscuity (the ability to catalyze different chemical reactions 
with different substrates) (2). These features are conducive for generating new enzymes 
with specialized functions through gene duplication and specialization (2-4). In an 
organism under environmental stress, which potentially requires new reactions to survive, 
specificity of activity can be selected by evolution. Low levels of promiscuous activities 
may persist in a specialized enzyme if they are not detrimental to the organism, and 
therefore there is no selective pressure for their elimination (5). Enzyme promiscuity can
also complement gene deletions in metabolic pathways, as in the case of phn operon 
knockouts in E. coli that recruit the phosphite-dependent hydrogenase activity of alkaline 
phosphatase (6), or E. coli auxotrophs that utilize promiscuous sugar kinases encoded by 
cryptic genes to rescue glucokinase deficient mutants (7). Thus, it has been suggested that 
promiscuity is an innate characteristic of all enzymes rather than an anomaly, and that 
there is a multitude of promiscuous activities extant in living cells merely waiting to be 
discovered.
In Chapter 2, the crystal structures of isopentenyl phosphate kinase from THA 
and MTH in ternary complexes with substrates and products were presented and became 
the newest structure in the AAK family of enzymes, which also includes NAGK, AK, 
CK, G5K, UMPK and FomA. In this family, IPK and the bacterial resistance protein 
fosfomycin kinase FomA in Streptomyces have very high structural similarity despite 
significant sequence divergence (22-25% identity). Moreover, the two enzymes possess 
the catalytic lysine triad and an active site histidine residue not found in other members 
of the family (8, 9). Thus, it was suggested that the ipk gene was the source of fomA, 
acquired by Streptomyces via horizontal gene transfer, and converted into a specialized 
fosfomycin kinase through mutation and selection (8, 10). This scenario is consistent with 
acquisition of resistance in bacteria constantly exposed to antibiotics (11). In the case of 
Streptomyces, fosfomycin kinase activity (Figure 3.1) was added to other resistance 
strategies in its arsenal, which includes fosfomycin inactivation by opening of the oxirane 
ring catalyzed by the metalloenzymes FosA, FosB and FosX (12-15) (Figure 3.2a and b).
In this chapter, the results of the investigation of the substrate promiscuity of IPK 
from Thermoplasma acidophilum (THA IPK) will be presented. THA IPK was tested for
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Figure 3.1 Fosfomycin inactivating reactions catalyzed by FomA and FomB found in the 
genomes of Streptomyces and Pseudomonas. FomA catalyzes the first phosphorylation 
step on fosfomycin, followed by FomB that adds the second phosphoryl group to make 
fosfomycin diphosphate. This product is unable to alkylate the active site cysteine residue 
of MurA, an enzyme critical for peptidoglycan synthesis.
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Figure 3.2 Mechanisms of fosfomycin ring opening reactions catalyzed by FosA and 
FosX. (Top panel) FosA uses a nucleophilic glutathione group in the active site to open 
the oxirane ring. FosB utilizes the same mechanism but uses a cysteine instead of 
glutathione. (Bottom panel) FosX is a hydratase that uses a water molecule to catalyze 
the ring opening reaction.
fosfomycin kinase activity and showed that the antibiotic is a promiscuous substrate for 
the enzyme, albeit with poorer binding affinity and a reduced rate of turnover. Moreover, 
fosfomycin is a competitive inhibitor of isopentenyl phosphate kinase activity at high 
concentrations. Using molecular dynamics simulations, two fosfomycin binding modes 
were discovered in which one is similar to that of IP in that it forms a stable complex 
with IPK, in addition to a separate binding mode that forms a dead-end complex.
Experimental Procedures
Materials. [32P] ATP was purchased from American Radiolabeled Chemicals. 
Disodium salts of fosfomycin (>99%), phosphoenolpyruvate (PEP) and nicotinamide 
adenine dinucleotide (NADH) were purchased from Sigma-Aldrich. Bovine serum 
albumin was purchased from Invitrogen. Lactate dehydrogenase (LDH, rabbit muscle) 
and pyruvate kinase (PK, rabbit muscle) were purchased from Roche. The concentrations 
of all reagents containing phosphates were determined by phosphate analysis, and the 
precise concentration of stock IPK enzyme was measured using the BCA Protein Assay 
Kit from Pierce.
Synthesis o f Isopentenyl Phosphate, IP (1). The procedure by Keller et al. was 
used to synthesize IP (16). Briefly, a dry solution of 3.46 g (17.4 mmol) 
triethylammonium phosphate (TEAP) in 15 mL of acetonitrile was added dropwise to 
astirred mixture of alcohol (isoprenol, 3.25 mmol) in 5 mL of trichloroacetonitrile at 
room temperature under N 2, in three equal portions with a 5 min interval between 
additions. The mixture was then concentrated at reduced pressure, giving a thick, dark 
orange oil. The resulting oil was chromatographed on silica gel using 2-
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propanol/NH4OH/H2O (6:3:1 v/v/v) and fractions containing pure products were 
combined. The solvent was removed by lyophilization, resulting in a white solid. 
Detection of IP was performed by thin layer chromatography using the same mobile 
phase and stained with p-anisaldehyde, R/ = 0.50 ; 1H NMR (D2O) 5 1.64 (s, 3H), 2.22 (t, 
2H, J  = 6 . 6  Hz), 3.79 (dt, 2H, J  = 6.9, 6.9 Hz), 4.69 (s, 1H), 4.73 (s, 1H); 31P NMR (D2O) 
5 1.13; HRMS (MALDI) calculated for C5H 11O4P [M-H] 165.0322, found 165.0317.
Cloning and expression o / THA IPK. The previous pET151/D-TOPO-THA IPK 
construct yielded proteins that were not trivial to purify. Due to the need for ultrapure 
proteins in kinetic experiments, a different construct based on the pET28b vector was 
constructed. The IPK gene in THA (TA0103) was amplified from genomic DNA (ATCC: 
25905D) with PfuUltra high fidelity DNA polymerase (Stratagene) using the primers 5’- 
TGA TGA TAC TGA AGA TAG GCG GAA G-3’ and 5’ -AAA AGC CAA GCT TAT TAT 
CTT ATC ACC GTA CCT ATG AAT GAT TC -3’. The PCR product was digested with 
HindIII and ligated into pET28b (Novagen) prepared by NdeI digestion, Pfu polishing, 
and HindIII digestion to give the plasmid pET-THA. BL21 (DE3) cells (Novagen) were 
transformed with pET28b-THA IPK and were grown on agar plates with kanamycin. An 
overnight culture (10 mL) was grown using a single colony from the plates and was used 
to inoculate 6 L of LB medium. The cultures were shaken at 37 oC until OD600 ~ 0.5 and 
induced with 1mM IPTG, and shaken at 30oC for another 6  h before centrifugation. Cell 
pellets were stored at -80 oC until needed.
Purification o f THA IPK. Frozen cell pellets were thawed on ice and resuspended 
in lysis buffer (50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 10 mM imidazole). Lysozyme 
(1 mg/mL) was added to the suspension and incubated for 30 min before sonication on
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ice. The crude lysate was centrifuged at 20,000 rpm at 4 oC for 25 min, and the resulting 
supernatant was incubated at 50 oC for 15 min followed by another centrifugation step. 
The supernatant was incubated with 5 mL Ni-NTA resin for 1 h at 4 oC with shaking (100 
rpm). The column was washed with five column volumes each of lysis buffer and wash 
buffer (50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 50 mM imidazole), before elution with 
25 mL of buffer (50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 250 mM imidazole) in 5mL 
fractions. SDS-PAGE was used to confirm the purity of the fractions, and those 
containing pure protein were combined, dialyzed at 4 oC against 20 mM Tris-HCl pH 8.0, 
containing 4 mM DTT, and stored in the same buffer containing 20% glycerol (v/v) as 
100 mL aliquots at -80 oC. Prior to kinetic experiments, proteins were quantitated using 
the BCA protocol (Pierce).
32Product turnover assay using y-[ P] ATP. The phosphorylation of fosfomycin by 
IPK was visualized by incubating the enzyme in assay buffer (100 mM HEPES pH 7.5 
containing 10 mM MgCl2, 10 mM P-mercaptoethanol, 1 mg/mL BSA, y-[32P] ATP and 
varying concentrations of fosfomycin at 37 oC for 10 min. Each reaction was quenched 
with 113 uL of methanol/750 mM EDTA (100:13 v/v). Samples (5 mL) were spotted on 
silica plates and developed with CHCl3/pyridine/formic acid/ H2O (30:70:16:10 v/v/v/v). 
The TLC plate was imaged for 24 h using a storage phosphor autoradiography cassette 
and visualized using a Typhoon 8600 variable mode imager (GE Healthcare). The same 
procedure was used in comparing the radioactive product of IPK with that of S. 
wedmorensis FomA, kindly provided by Dr. Kate Slessor. The mixtures each contained 
10 mM of fosfomycin and 10 uM enzyme, and incubated at 37 °C for 2 h.
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MS/MS fragmentation o f fosfomycin phosphate product. In order to confirm the 
presence of the fosfomycin phosphate product by IPK, we performed an MS/MS 
fragmentation experiment on the ammonium form of fosfomycin phosphate (mass = 236) 
produced by IPK and FomA. The said products were obtained by incubating 20 .^M of 
each enzyme in assay buffer (100 mM HEPES pH 7.5, 1 mg/mL BSA, 10 mM P- 
mercaptoethanol, 10 mM MgCl2) containing 25 mM fosfomycin at 37 °C for 2 hr, in a 
total volume of 1 mL. The enzymes were removed by centrifugation using a 10, 000 
MWCO Centricon, and the filtrate was flash frozen in liquid N2 and lyophilized overnight 
in 1.5 mL microfuge tubes. The resulting slurry was dissolved in 100 ^L of 25 mM 
NH4 HCO3 and submitted for MS/MS fragmentation.
Measurement o f the activities o f coupling enzymes. The activities of coupling 
enzymes were determined by measuring the change in absorbance of NADH at 339 nm. 
Different concentrations of lactate dehydrogenase (LDH) were mixed in the assay buffer 
(100 mM HEPES containing 10 mM MgCl2, 10 mM P-mercaptoethanol, 1 mg/mL BSA, 
120 .^M pyruvate and 150 .^M NADH) at 37 oC. For pyruvate kinase, different 
concentrations of the coupling enzyme were mixed in assay buffer (100 mM HEPES 
containing 10 mM MgCl2, 10 mM P-mercaptoethanol, 1 mg/mL BSA, 1 mM PEP, 4 mM 
ADP, 150 .^M NADH and LDH) at 37 oC. The enzymatic rates in AU/s where converted 
to specific activity units (U/mL) by using the NADH extinction coefficient s = 6.22 mM-1 
cm-1.
Steady state kinetics o f the IPK-fosfomycin reaction. The protocol for fluorescent 
assays was based on the procedure by Pilloff et al. with slight modifications (17). To 
initiate the reaction, IPK was added to the assay buffer (100 mM HEPES pH 7.5
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containing 10 mM MgCl2, 10 mM P-mercaptoethanol, 1 mg/mL BSA and ATP) 
including appropriate amounts of coupling enzymes and fosfomycin (or the native 
substrate IP for positive control reactions) in a final volume of 200 .^L. The reaction was 
monitored at 37 oC for 600 s by observing the change in fluorescence (^ex = 340 nm, ^em 
= 460 nm) (FluoroMax, Jobin Yvon Horiba). Background rates were measured at 
different concentrations of fosfomycin in the absence of the enzyme and were averaged. 
The initial rates were measured from the linear portion of the curve (< 15 % 
consumption of the concentration-limiting substrate). The kinetic constants were 
determined by fitting the matrices of initial rates to equation 1 using Grafit 5 (Erithacus 
Software) (18):
V = Vmax [A][B] / KdAKuB + KmB [A] + KmA [B] + [A][B] (1)
where A and B are fosfomycin and ATP, Vmax is the maximum rate, KM is the Michaelis- 
Menten constant and Kd is the enzyme dissociation constant. The lag time t  of the 
coupled assay is given by the equation
t  = KmADP/VPK + KMPyr/VLDH (2)
where K j ^ 1" = 0.3 mM according to Sigma and KMPyr = 0.164 mM according to Zewe 
and Fromm (19) and V is the activity of the enzyme in U/mL. The lag time t  of the 
reaction was then chosen to be less than 10 s, which ensured that the system reached 99 
% of the steady state rate of ADP production in 45 s according to the equation
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dP/dt = V0 (1 -  e't/x) (3)
where v0 is the steady state rate and t and t  are in min.
Competitive inhibition of IP kinase activity by fosfomycin. Different 
concentrations of IP and fosfomycin were added to the assay buffer (100 mM HEPES pH 
7.5 containing 10 mM MgCl2, 10 mM P-mercaptoethanol and 1 mg/mL BSA). The 
reaction was initiated by mixing a solution of IPK in the same buffer with the first 
solution followed by incubation at 37 oC for 600 s. Initial rates were measured as 
described for the fluorescence assay, and the inhibition constant Ki was determined by 
fitting the initial rate matrices to the equation for competitive inhibition:
where S is the substrate IP and I is the competitive inhibitor fosfomycin.
Molecular dynamics simulations o f the IPKfosfomyciwMgATP complex. 
Molecular dynamics simulations were performed using GROMACS (20) with 
CHARMM27 (21) force field for proteins and small molecules (22) and TIP3P (23) for 
water. The initial structure of the kinase is derived from the crystal structure of IPK (8), 
while the specific binding pose of ligands in the binding pocket of IP K  
fosfomycin*MgATP was derived from the superposition of structures 3LKK (IPK) and 
3D41(FomA). The missing loop and aF helix of IPK (residues 189-201) were modeled 
based on sequence and structure alignment with NAGK (1GS5) where the corresponding
V Vmax [S] / [S] + Km( 1 + [I]/Ki) (4)
secondary structures in the latter most approximate the length of these missing regions 
(Figure 3.3a and b). The geometry of the modeled secondary structures was validated 
using Molprobity (24). After an initial rapid energy minimization, the system was 
equilibrated by performing a position-restrained NVT simulation for 100 ps followed by 
an NPT run for another 100 ps. We then performed an unconstrained production run for 
30 ns to validate the initially hypothesized poses of fosfomycin and MgATP. Long-range 
electrostatics was treated with Particle Mesh Ewald (25) with grid spacing of 12 A and a 
cutoff of 10 A. We used the modified Berendsen (26) and Parrinello-Rahman (27) 
algorithms for temperature and pressure couplings, respectively. The same experiments 
were performed on the native IPK^IP^MgATP complex as a control.
Site-directed mutagenesis o f THA IPK. To create the Lys14Ala and Lys204Ala 
mutants, the forward primers 5’-GGC GGA AGC GTG ATC ACC GAT GCA TCC GCT 
TAC CG-3’ and 5’-GTT ACC GGC GGT ATA GGG GCG AAG TTC GAA TCC ATG GT-3’ 
were designed. PCR reactions were carried out following the protocol in the Quikchange 
Site-Directed Mutagenesis Kit manual (Stratagene)
Results
32Detection o f promiscuity. Autoradiography studies using y-[ P] ATP showed that 
fosfomycin is an alternate substrate for IPK. The formation of the product was
32accompanied by a concomitant decrease in y-[ P] ATP when the concentration of 
fosfomycin was in the high |jM to mM range (Figure 3.4a). In contrast, KMIP = 4.4 ^M 
for THA IPK. The product of the promiscuous reaction, assigned as fosfomycin 
phosphate, is consistent with the intense spot with R/ = 0.14 relative to IPP, R/ = 0.37.
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Figure 3.3 Sequence and structure alignment of IPK and NAGK enzymes. (Top panel) 
Superimposed IPK (green) and NAGK (red) structures showing the missing aF helix and 
the loop that connects it to the aG  helix. (Bottom panel) Sequence alignment of 
homologous enzymes showing the stretch of sequence in NAGK used to model the 
missing structures in IPK.
116
Figure 3.4 Autoradiogram showing that IPK can phosphorylate fosfomycin in the 
presence of ATP. (a) The product of the native reaction, P-[32P] IPP, and the byproduct of 
the intrinsic ATPase activity, 32Pi , migrate with almost similar R/s. This ATPase activity 
is independent of fosfomycin concentration. Increasing phosphorylation of fosfomycin is
32observed in the ^M to mM range. All lanes except lane 13 contained y-[ P] ATP and 200 
nM IPK. (1) 3.5 |^M IP and IPK, (2) 300 nM fosfomycin, (3) 900 nM, (4) 3 ^M, (5) 9 
I^M, (6 ) 27 |^M, (7) 81 |^M, (8 ) 210 ^M, (9) 630 ^M, (10) 2 mM, (11) 6  mM, (12) 18 
mM, (13) [14C] IPP, (14) y-[32P] ATP and IPK. (b) Comparison of the products of S. 
wedmorensis FomA and IPK. (1) [14C] IPP, (2) FomA and fosfomycin, (3) IPK and 
fosfomycin, (4) FomA without fosfomycin, (5) Fosfomycin without enzyme.
This spot did not appear in control reactions containing only IP or y-[ P] ATP and IPK. 
In addition, incubation of FomA and IPK showed product spots with the same Rf s as 
above (Figure 3.4b). These product spots were not found in incubations containing either 
enzymes or fosfomycin substrate. MS/MS fragmentation of the ammonium form of 
fosfomycin monophosphate (mass = 236) coming from incubates with IPK and FomA 
resulted in identical fragmentation patterns. Positive ion species corresponding to 
[C3H5O]+ (mass = 57), [C3H6O3P]+ (mass = 121), [H4O4P]+ (mass = 99), and [C3H8O4P]+ 
(mass = 139) were found in the fragmentations of fosfomycin monophosphate produced 
by either IPK or FomA. The first two cations, [C3H5O]+ and [C3H6O3P]+ were also 
observed in the fragmentation of a fosfomycin standard (see Appendix).
31In P NMR assays, resonances corresponding to a phosphonate-phosphate moiety 
were not detected owing to the slow reaction and an apparently unfavorable equilibrium 
between fosfomycin-ATP and fosfomycin phosphate-ADP. We initially attempted longer 
incubation times without success. The autoradiogram shows a byproduct of the kinase 
reaction whose Rf is similar to that of IPP (Figure 3.4a), which is more pronounced in the 
absence of fosfomycin (Figure 3.4b, lane 4). Chen and Poulter (10) had previously shown 
that this by-product is 32Pi, resulting from the combined effects of y-[32P] ATP 
degradation and the intrinsic ATPase activity of IPK. ATPase activity has been observed 
in many kinases and is commonly negligible compared to native kinase activities (28), 
although in some cases is sufficiently large to interfere with their precise measurements 
(29). The ATPase activity of THA IPK was found to be sufficiently small (~ 200 times 




Kinetic constants o f the promiscuous reaction. The ability of IPK to 
phosphorylate a variety of other phosphorylated small molecule substrates was recently 
reported by Chen and Poulter (10) and Dellas and Noel (9). This promiscuity can now be 
extended to a small molecule bearing a phosphonate group. Initially, a series of 
fosfomycin concentrations ranging from 750 ^M to 90 mM was used to measure the 
apparent kinetic constants of the reaction at saturating ATP concentration (Figure 3.5). 
These experiments showed that IPK could be saturated with fosfomycin and allowed us 
to identify a suitable range consisting of four different fosfomycin and ATP 
concentrations. Initial rate matrices were fitted to the equation for bisubstrate reactions 
(Figure 3.6a) and were transformed to a Lineweaver-Burk plot (Figure 3.6b). The 
fosfomycin kinase reaction proceeds by the same sequential mechanism seen for IP and 
ATP. The kinetic constants for the promiscuous and native activities of THA IPK are 
summarized in Table 3.1.
Fosfomycin is a competitive inhibitor o f IPK. The kcat for the promiscuous activity 
of IPK is at least two orders of magnitude smaller than that of the native kinase activity 
(Table 3.1). Moreover, superposition of the THA IPK and FomA ternary complexes 
aligned the respective IP and fosfomycin substrates (Figure 3.7). These kinetic and 
structural data indicate that fosfomycin can act as a competitive inhibitor of the faster IP 
kinase reaction. Kinetic studies with varying concentrations of fosfomycin were 
performed. The best fit was obtained with the equation for competitive inhibition
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Figure 3.5 Michaelis-Menten saturation curve for IPK using fosfomycin as a substrate. 
Maximum specific activity is reached at high mM concentrations of fosfomycin.
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Figure 3.6 Fosfomycin is a promiscuous substrate of IPK. (a) Michaelis Menten curve 
showing saturation of IPK at high mM concentrations of fosfomycin. A high KM (15.1 
mM) indicates weak binding of fosfomycin to the IP binding site. (b) Lineweaver-Burk 
transformation of (a), indicating a sequential binding mechanism and formation a ternary 























kcat (s ) 8 .0  (± 0 .2 ) 4 (± 0.1) x 10-2 7.7 (± 0.2) 2.7 (± 0.1) x 10-2
Km(!^ M) 4.4 (± 0.5) 1.5 (± 0.1) x 104 2.8 (± 0.3) 1 .1  (± 0 .1) x 1 0 4
kcaK  (M V ) 1 .8  x 1 0 6 2 . 6 2 . 8  x 1 0 6 2.5
KmATP (mM) 6.0 (± 0.5) 1.4 (± 0.1) 6.9 (± 0.6) 1 .2  (± 0 .2 )
Kd (mM) 4.6 (± 1.5) 1.8 (± 0.3) x 104 4.6 (± 1.3) 1.5 (± 0.5) x 104
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Figure 3.7 T. acidophilum IPK and S. wedmorensis FomA have high level of structural 
similarity. (a) Superimposed crystal structures of IPK (3LKK, green) and FomA (3QUO, 
blue) have RMSD of 2.6 A over 224 amino acid residues. The substrates of IPK (IP and 
ATP, black) and FomA (fosfomycin and ATP, pink) also align well in their respective 
active sites. The divalent metal Mg2+ is shown as a purple sphere. (b) Alignment of 
catalytic residues invariant in IPK and FomA, suggesting similar mechanisms of 
phosphoryl transfer. The FomAfosfomycin^MgATP complex was modeled using the 
structures of the FomA^MgATP (3QUN) and FomAfosfomycin^ATP (3QUO) 
complexes. Distances between the nucleophilic oxygen atoms of IP or fosfomycin and 
the electrophilic P atom being attacked are indicated.
where S is the substrate IP and I is the inhibitor fosfomycin. The Michaelis-Menten 
curves (Figure 3.8a) showed an apparent increase in KMIP with increasing inhibitor 
concentration, while at saturating concentrations of IP, the inhibitory effects of 
fosfomycin are overcome. The Lineweaver-Burk transformation of these curves showed 
an array of intersecting lines on the ordinate (Figure 3.8b), with kcat = 7.5 s-1, similar to 
the reported value in the literature (8.0 s-1) and Ki = 3.6 ± 0.20 mM. Weak inhibition of 
THA IPK by fosfomycin is most likely due to the incompatibility of its polar epoxide 
group with the hydrophobic pocket tailored to the aliphatic tail of IP.
Binding poses o f FomA in IPK. The kinetic data and the highly analogous 
structures of IPK and FomA strongly suggest that the native substrate IP and the 
promiscuous substrate fosfomycin adopt similar binding poses in IPK. To examine this 
issue, molecular dynamics simulations of the presumed pose of fosfomycin were 
performed using the superimposed structures of the IPK and FomA ternary complexes. 
To fix the MgATP ligand in its binding site during simulation, an accurately modeled 
structure for the missing aF -aG  loop and aF  helix of IPK was supplied to the starting 
structure based on the aligned sequences of IPK from T. acidophilum and M. 
thermautotrophicus (8), S. wedmorensis FomA (30) and E. coli NAGK (24) (Figure 3.3). 
These alignments indicate that the secondary structure in NAGK, which only differs from 
the sequence in THA IPK by a single amino acid, can be used to model the missing loop 
and aF  helix in IPK. The system is stable and has an average C a RMSD of 1.5 A with 
respect to the starting structure (Figure 3.9a and b). The heavy atom RMSD of 
fosfomycin and ATP were also computed and showed two stable conformers of 
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Figure 3.8 Fosfomycin is a competitive inhibitor of IPK. (a) Michaelis Menten curve 
showing an increase in KMIP with increasing fosfomycin concentration. (b) Lineweaver- 
Burk transformation of (a) showing a family of lines intersecting at the y-axis, indicating 
a constant Vmax. (°) 0 mM fosfomycin, (•)  1 mM fosfomycin, (□) 2 mM fosfomycin, (■) 

















Figure 3.9 Energy (a) and RMSD time-series (b) showing that the modeled 
IPKfosfomycin^MgATP complex is stable.
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Figure 3.10 Ligand (fosfomycin and ATP, left) RMSD (a) and histogram (b) showing a 
two-state binding conformation for fosfomycin, while ATP is essentially fixed.
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support the observed two-state conformation (Figure 3.10b). Closer inspection of these 
two conformations shows that fosfomycin binds to the N-terminal lobe of THA IPK that 
contains the IP binding site (Figure 3.11).
In both complexes, fosfomycin can obstruct the IP binding site, supporting the 
observed competitive mode of inhibition. Moreover, in both complexes the MgATP 
conformation is essentially fixed while fosfomycin is translated by a few A (3.9 A in the 
first pose and 4.8 A in the other pose) away from the location of IP in the binding site, 
presumably to reduce unfavorable interactions between the polar epoxide and the 
hydrophobic binding pocket (Figure 3.11). In the first binding pose (Figure 3.12a), the 
oxygen of the epoxide is oriented toward the solvent region while the methyl group packs 
into the hydrophobic pocket. The catalytic residue His50 in the aB helix forms a 
hydrogen bond with the phosphonate group, analogous to its interaction with IP. The Ns1 
nitrogen atom is the hydrogen bond donor in this binding pose, instead of the Ns2 
nitrogen atom observed in the crystal structure (8). Nevertheless, this interaction 
positions fosfomycin for attack on ATP, where the y-phosphate is 5.1 A away. This is 
substantially longer than the 2.9 A distance between the IP phosphate and y phosphate of 
ATP in the IPK ternary complex (3LKK) and likely contributes to the low efficiency of 
the promiscuous reaction. However, the distance between the phosphonate group and the
Y phosphate of ATP in the structure of the FomA^fosfomycin^MgATP complex, modeled 
from coordinates of the FomA^MgATP (3QUN) and the FomA^fosfomycin^ATP 
(3QUO) complexes, is 4.0 A (Figure 3.7) (30). Thus, it is likely that this distance is a 
good approximation of the real phosphonate-Y-phosphate distance. Examination of this 
binding pose also reveals the active site Mg2+ is located 3.7 A from a phosphonate
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Figure 3.11 Superposition of the two observed binding poses (purple and pink) of 
fosfomycin to that of IP in its binding site in IPK. The two hydrophobic residues in the 
IP binding site, Met77 and Tyr127, are shown as sticks to emphasize the incompatibility 
of the polar fosfomycin epoxide ring to this site, resulting in the translation of fosfomycin 
away from the site in both poses. The catalytic residues of IPK that are conserved in 
FomA are shown as sticks. The ATP molecules are colored as the corresponding IP or 
FomA substrate.
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Figure 3.12. Binding poses of fosfomycin in the IP binding site of IPK. (a) Fosfomycin 
in the first orientation or pose. (b) Fosfomycin in the second orientation or pose.
oxygen, perhaps facilitating nucleophilic attack on ATP. This interaction as well as innate 
enzyme plasticity could help overcome the ~5 A distance between reactive phosphonate 
and phosphate centers. The interactions of Lys5, Lys14, Lys205 and Asp144 observed in 
the IPK^IP^ATP complex (8) are essentially conserved in this binding pose.
In the second, less populated binding state, fosfomycin is removed even farther 
away from the precise IP binding site, eliminating hydrogen bonding with His50 and 
causing hydrogen bonds to form between the epoxide group and Ser142, and between the 
phosphonate group and Lys204 in the aG  helix. In THA IPK, Ser142 binds the phosphate 
group of IP. This residue is conserved in FomA and orients fosfomycin for nucleophilic 
attack on ATP by hydrogen bonding with the epoxide O atom (29). In addition, the 
phosphonate group is 6.3 A away from the y phosphate in ATP and 4.1 A from Mg2+ in 
this second pose (Figure 3.12b).
Molecular dynamics simulation of IPK^IP^MgATP showed that the complex is 
stable (Figure 3.13) and revealed a single binding pose with IP and MgATP virtually 
unchanged from their respective poses in the crystal structure (Figure 3.14). The latter 
result suggests that the crystal structure closely approximates the structure of the complex 
in solution and also lends credence to the two observed binding poses of fosfomycin in 
the IPK active site.
The K204A mutant IPK has fosfomycin activity comparable to the wild type IPK. 
The recruitment of Lys204 to form a hydrogen bond to an oxygen atom of the 
phosphonate moiety appears in the simulation to “rescue” the His50-phosphonate 
hydrogen bonding interaction absent in the second binding complex. To validate the 


















Figure 3.14 Ligand (IP and ATP) RMSD showing a single-state binding conformation 
for IP and ATP.
catalysis, a Lys204Ala mutant was purified and assayed for fosfomycin kinase activity. 
This mutant remained active and was saturated with fosfomycin at high mM 
concentrations like the native enzyme (Figure 3.15). There was only a 33% decrease in 
the turnover number kcat as well as in the Michaelis constant, KM, for fosfomycin, while 
the catalytic efficiency kcatIKM remained unchanged (Table 3.1, Column 5). Moreover, the 
mutation did not affect catalysis of the native reaction (Table 3.1, Column 4, Figure 
3.16), as the kinetic parameters remained unchanged from those previously reported (10).
Discussion
Fosfomycin is a secondary metabolite produced in several species of 
Streptomyces (31) and Pseudomonas (32) that is widely used clinically to treat cystitis 
(33) as well as methicillin- and vancomycin-resistant strains of Staphylococcus aureus 
(34,35). Its bactericidal activity is based on the inhibition of MurA (36) by the 
irreversible alkylation of an active site cysteine residue, preventing the first step in 
peptidoglycan synthesis in which PEP is linked to the 3’-hydroxyl group of UDP-N- 
acetyl-glucosamine (Figure 3.17) (37). Bacterial resistance to fosfomycin is achieved by 
mutations in MurA and by alterations in the glycerophosphate transporter (38, 39). In 
addition, fosfomycin is inactivated by hydrolysis of the epoxide moiety by the thiol 
transferases FosA and FosB, and the homologous hydratase enzyme FosX (Figure 3.2a 
and b) (12-15, 40). Two additional enzymes, FomA and FomB, alter the antibiotic by 
two consecutive phosphorylation steps resulting in a product unable to alkylate the 
relevant cysteine residue in MurA. The fomA and fomB genes are found in the fosfomycin
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Figure 3.15 Michaelis-Menten curves from kinetic studies on the Lys204Ala IPK mutant 
with fosfomycin. (a) Kinetic measurements using fosfomycin as substrate showed that the 
mutant can catalyze the promiscuous reaction to the same extent as native THA IPK. (o)








Figure 3.16 Michaelis-Menten curves showing that the Lys204Ala mutant can catalyze 
the native reaction (using IP as substrate) to the same extent as native THA IPK. (o) 10 
I^M ATP, (•)  20 |^M ATP, (□) 40 ^M ATP, (■) 80 ^M ATP.
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Figure 3.17 Comparison of the IPK and FomA binding sites. The hydrophobic side chain 
residues of both IPK and FomA are shown. The IP binding site of IPK is made of mainly 
hydrophobic residues, with Met77 and Tyr127 immediately below the aliphatic tail of IP. 
The fosfomycin binding site in FomA also contains some hydrophobic side chains aside 
from hydrophilic ones of Thr79, Lys83 and Ser51.
biosynthetic gene clusters of Streptomyces and Pseudomonas and are thought to confer 
resistance and facilitate transport in these hosts (41, 42).
The phosphate subdivision of the AAK family of enzymes consists of IPK, 
FomA and uridine monophosphate kinase (UMPK) (8, 9, 43). These three enzymes 
catalyze phosphoryl transfer from ATP via nucleophilic attack by an oxygen atom in a 
phosphate or phosphonate group in a reaction that proceeds through a pentavalent 
transition state intermediate (8, 30, 43). Within this subdivision, IPK and FomA 
displayed significant structural similarity. Moreover, superposition of crystal structures 
for IPK»IP»ATP and the modeled structure of the FomA»fosfomycin»MgATP complex 
showed good alignment of their catalytic residues and respective substrates. The 
structural similarities between THA IPK and S. wedmorensis FomA suggest an 
evolutionary relationship between the two proteins, with an archaeal IPK as the likely 
ancestor. In that case, IPK might possess promiscuous activity toward the substrate for 
FomA, as is the case with many enzymes within a family (8,9).
We measured the kinetic parameters for the promiscuous fosfomycin kinase 
activity of IPK by coupling the production of ADP to the oxidation of NADH, using 
pyruvate kinase and lactate dehydrogenase as coupling enzymes (17). The turnover 
number, kcat for the promiscuous reaction (0.04 s-1) is 200-fold lower than that for the 
native activity (8 . 0  s-1), while the Michaelis constant (KM) for fosfomycin (15.1 mM) is 
more than three orders of magnitude greater than that for IP (4.4 mM). The catalytic 
efficiency for phosphorylation of fosfomycin by THA IPK (kcatIKM = 2.5 M-1s-1), while 
five orders of magnitude lower than for phosphorylation of IP, could still serve as starting 
point for evolution of a more potent fosfomycin phosphorylation enzyme. There are
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notable examples in the literature of enhancement of secondary enzyme activities 
achieved by mutation of one or more residues in the active site. For instance, the E. coli 
RTEM P-lactamase increased its secondary cephalosporinase activity 1.4-fold and 
decreased its primary penicillase activity 3-fold upon placement of the bacterial strain 
under the selective pressure of cephalosporin C, and the observed changes in activity 
were caused by two mutations in the active site (44). Subsequently, other mutations were 
found to cause more dramatic improvements in cephalosphorinase C activity, such as the 
Ala237Asn mutation observed by Healey et al. (45) and different mutant combinations 
observed by other groups (46, 47).
The reduction in catalytic efficiency results primarily from the conformation of 
fosfomycin in the IP binding site relative to the native substrate. This site is laden with 
hydrophobic residues that cradle the aliphatic tail of IP and dictate the size of the 
isoprene moiety that can be accommodated in the active site (8, 9). Fosfomycin, although 
smaller than IP, contains a polar epoxide group that appears to reduce binding to the 
hydrophobic pocket. A comparison of the active sites of FomA and IPK shows that the 
latter has a more hydrophobic region immediately below the aliphatic tail of IP, arising 
primarily from the side chains of Met77 and Thr127 (Figure 3. 17a) (8). Similar residues 
are not found in the corresponding site of FomA (Figure 3.17b) (10). Moreover, Ser149, 
which is crucial in binding fosfomycin in FomA, is replaced by a glycine residue in THA 
IPK and MTH IPK (30, Figure 3.3, lower panel). Amino acids Gly53, His58 and Ser148 
in FomA create a constellation of possible hydrogen bond donors to the epoxide group 
and phosphonate groups of fosfomycin. Although a similar hydrogen bonding network is 
possible in IPK (8, 9), the immediate vicinity of the epoxide ring in FomA is not as
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hydrophobic as the corresponding region in IPK (Figure 3.18a and b). In addition, the 
side chains of Thr79, Lys83 and Ser51 enhance the hydrophilicity of the fosfomycin 
binding site in FomA (Figure 3.17b). It was then not surprising that in both binding poses 
observed during simulation, fosfomycin was translated by a few Angstroms away from 
the IP binding site to relieve the unfavorable interactions between the hydrophobic pocket 
and the polar epoxide group, and in the first pose, to orient the epoxide group toward the 
solvent. These new positions still place fosfomycin in a blocking position in the IPK 
binding site, consistent with it being a competitive inhibitor of IP. Thus, the differences 
between the hydrophobicities of the active sites of IPK and FomA and the absence of a 
corresponding residue for Ser149 in THA IPK, explain the high KM for the promiscuous 
substrate.
The low level of promiscuous activity of IPK can be explained by 
phosphorylation occurring in the first binding pose for fosfomycin, where the antibiotic 
forms a hydrogen bond with His50, the catalytic residue responsible for orienting the 
substrate for nucleophilic attack on ATP in the native reaction. Although the distance 
between the nucleophilic phosphonate group and the y-phosphate group of ATP is longer 
than the phosphate group in the native reaction (Figure 3.7), it is similar to the native 
IPK*IP*ATP structure and can therefore be reasonably assigned as a productive complex. 
In addition, this binding complex engages the conserved Lys14 in the same interactions 
observed in the IPK^IP^ATP complex (Figure 3.12a). Lys14 binds the phosphate group 
of ATP in the IPK^IP^ATP complex and is positioned to stabilize the highly negatively 
charged transition state (8). These roles have been confirmed biochemically, with the
ATPLys14Ala mutation resulting in a two-fold increase in KM and a 460-fold decrease in
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Figure 3.18 Side chains of residues in the IPK (a) and FomA (b) active sites that help 
orient IP and fosfomycin for nucleophilic attack by hydrogen bonding. Although Ser142 
in IPK is in a different conformation in the crystal structure than the corresponding 
residue in FomA, it can undergo rearrangement to form a hydrogen bond as the 
corresponding serine residue in FomA (b).
kcat compared to the native enzyme. The same mutation on the corresponding Lys18 
residue in FomA resulted in an inactive enzyme (30). The structure of the second 
complex suggests that it is not suitable for catalysis and can be reasonably assigned as a 
dead-end complex. Much longer simulation runs may reveal other binding poses of 
fosfomycin that converge quickly toward the productive binding pose, making it nearly 
impossible to deconvolute the contribution of each pose to catalysis.
Our observations highlight characteristics for IPK that have more general 
implications, namely the structure of the active site accommodates related reactions with 
promiscuous substrates, although the promiscuous activity does not always utilize the 
active site residues in the same manner as the native reaction (5). Moreover, bi- or even 
multimodal binding of promiscuous substrates is a direct consequence of these 
characteristics and could give rise to multiple products from a single promiscuous 
substrate.
Our results suggest a possible scenario for the evolution of a bacterial FomA 
from an archaeal IPK by horizontal transfer of an archaeal ipk gene to Streptomyces, 
followed by adaptive mutations that confer antibiotic resistance. This requires a sufficient 
level of promiscuous fosfomycin activity of IPK to provide an advantage for selection of 
FomA activity in the presence of environmental pressure (fosfomycin) (4). IPK is an 
enzyme found exclusively in the alternate mevalonate route for biosynthesis of IPP in 
Archaea, most of which is incorporated into the phytanyl and diphytanyl chains of their 
cell membrane phospholipids (48). Bacteria and Eukarya synthesize IPP by different 
pathways. Thus, the translocated ipk gene initially did not have a metabolic function in 
the receiving bacterium and was immediately available for specialization as a fosfomycin
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resistance gene. Activities with catalytic efficiencies similar to the fosfomycin kinase 
activity of IPK have been shown to confer immediate selective advantage, as in the case 
of phosphonate monoester hydrolase in Burkholderia caryophili (9.5 M-1s-1), which 
allowed this organism to thrive on glyceryl glyphosate, a previously unencountered 
phosphorous source (49-51). Even a catalytic efficiency as low as 0.3 M-1s-1 (E. coli 
glutamine phosphoribosylpyrophosphate amidotransferase) can provide a similar 
advantage, although in this organism the gene was overexpressed from a multicopy 
plasmid under control of a strong promoter (52). Moreover, a phylogenetic tree of IPK 
homologues clustered the S. wedmorensis and S. fradiae FomA enzymes with archaeal 
IPKs, making this case of horizontal gene transfer from Archaea to Bacteria a viable 
scenario (10, Figure 1). Likely instances of horizontal transfer of metabolic genes 
between Archaea and Bacteria (and other interdomain HGTs) have been pointed out, as 
in the acquisition of mevalonate pathway genes from Archaea (or Eukarya) by Borrelia 
and Cocci, or of the bacterial glycerol dehydrogenase gene acquired by Archaea, which 
was possibly co-opted for glycerol-1-phosphate dehydrogenase activity (53).
The substrate promiscuity of IPK towards fosfomycin and the highly conserved 
catalytic site residues and similar folds of IPK and FomA indicate a genetic connection 
between the two proteins, even though they only share 20-25% identity at the amino acid 
level. The fact that IPK is found in all representatives of Archaea with sequenced 
genomes while FomA is only found in two strains of Streptomyces and in one strain of 
Pseudomonas suggests that the bacterium acquired an archaeal copy of an IPK gene by 
horizontal gene transfer, which was subsequently optimized for FomA activity. Our 
findings underscore the gene duplication/horizontal transfer mechanism for evolution of
144
145
new enzyme activities, including new metabolic pathways, from enzymes available in the 
cell.
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CHAPTER 4
ISOPENTENYL PHOSPHATE KINASE MUTANTS WITH GERANYL 
PHOSPHATE AND FARNESYL PHOSPHATE 
KINASE ACTIVITIES
Introduction
Directed evolution and structure-based redesign are two approaches whereby 
wild-type enzymes are conferred with novel activities (1). Well-documented examples of 
these protein engineering strategies are found in the literature, resulting in mutants with 
improved catalytic efficiencies and selectivities for nonnatural substrates. In the case of 
prenyltransferases and isoprenoid synthases, several studies have been performed in 
which their chain length selectivities and ultimate product chain lengths were altered. For 
instance, Ohnuma et al. used a random chemical mutagenesis approach to generate 
mutants of Bacillus stearothermophilus farnesyl diphosphate synthase (FPPS) with 
geranylgeranyl diphosphate synthase (GGPPS) activity (2). The selection was 
accomplished by monitoring the formation of GGPP in vivo using the Erwinia uredovora 
carotenoid biosynthesis enzymes, phytoene synthase and phytoene desaturase, such that 
successful mutant colonies displayed a red coloration coming from lycopene. The study 
resulted in the identification of an aromatic active site residue, Tyr81, whose mutation to 
a smaller side chain (histidine) was essential for GGPP synthase activity. This change in
ultimate product chain length specificity came at the expense of catalytic activity, so that 
mutants harboring the Tyr81His mutation have GPPS activities lower than the wild-type 
FPPS activity. Interestingly, it was also found that the Michaelis constant, KM, of IPP 
changed depending on the allylic primers used, indicating that the mutant enzymes 
possessed different affinities to the same substrate depending on the countersubstrate, a 
phenomenon that might arise from conformational changes upon binding of the latter (2).
Follow-up experiments by Ohnuma et al. corroborated the importance of the 
position occupied by Tyr81 in B. stearothermophilus FPPS in determining ultimate chain 
length specificity (3). Comparison of isoprenoid synthase enzymes from different 
organisms showed that the corresponding residues occupy the fifth position upstream of 
the first DDXXD motif, one of two aspartate-rich sequences that serve as binding sites for 
the diphosphate moieties of IPP and allylic substrates (4-16). The fifth position is 
occupied by aromatic side chains (phenylalanine and tyrosine) in archaeal FPPS and 
GGPPS. On the other hand, polyprenyl diphosphate synthases that catalyze the 
condensation beyond GGPP in organisms other than Archaea have a non-aromatic amino 
acid at this position. Thus, transmutation of Phe77, which occupies the fifth position in 
Sulfolobus acidocaldarius GGPPS, to either serine or leucine resulted in mutants that can 
catalyze the condensation of IPP to form geranylfarnesyl diphosphate (GFPP) and 
hexaprenyl diphosphate (HPPS) (2). These mutants were generated and identified using 
random chemical mutagenesis and a complement system of a yeast mutant deficient in 
HPPS activity. Further studies by Ohnuma et al. on the S. acidocaldarius GGPPS 
showed the fifth position before the first DDXXD motif to be but a part of a larger region 
that determines ultimate chain length specificity, thereby called the chain length
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determination (CLD) region that starts at the fifth position up to the end of the first 
asparate-rich motif (17). This CLD region was previously shown by Tarshis et al. to form 
an a  helix, where the distance between the aspartate (Asp177) in the first DDXXD motif 
and the amino acid in the fifth position is about 10-12 A, similar to the length of the FPP 
hydrocarbon chain (18). Indeed, the CLD region blocks further elongation beyond the 
limit of the chain length of product determined by the specificity of each enzyme.
The three-dimensional structure of the avian FPPS also guided the construction 
of mutants with GPPS activity. Stanley Fernandez et al. used modeling and mutagenesis 
studies to identify the Ala116Trp mutation adjacent to Asp117 of the first DDXXD motif 
that caused the highest improvement in GPPS activity among seven designed mutants 
(19). Moreover, a similar level of activity was found for the Asn144’Trp mutant, 
although in this instance Asn144 is found across the binding pocket from Ala116 on the 
other polypeptide chain in the homodimer. These two mutants possessed 63- and 28-fold 
improvements in kcatIKM for the synthesis of GPP relative to FPP. These examples thus 
demonstrate the utility of directed evolution and structure-based engineering in 
expanding the activities of isoprene synthases.
In another case, structure-based engineering was exploited in the conversion of 
the chain length specificity of prenyltransferases. These enzymes catalyze the attachment 
of lipid moieties to proteins. This process, called prenylation, is important in the 
localization of target proteins to the cellular membrane. Eukaryotic cells harbor three 
kinds of protein prenyl transferases: protein farnesyltransferase (pFTase), protein 
geranylgeranyl transferase type I (pGGTase I) and protein geranylgeranyl transferase 
type II (pGGTase II or Rab GGTase), whose substrates are limited to the Rab subfamily
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of G proteins (20). On the other hand, pFTase and pGGTase I prenylate proteins that 
include members of the Ras superfamily of GTPases, several protein kinases and 
phosphatases, and several proteins involved in centromere function and nuclear integrity 
(21,22). pFTase in particular transfers the 15-carbon farnesyl chain while pGGTase I 
transfers the 20-carbon geranygeranyl chain to the cysteine residue of a C-terminal 
Ca1a2X motif of the substrate protein (20). In this motif, C refers to the cysteine residue, 
a1 and a2 represent any small aliphatic residue, and X determines the whether the protein 
is farnesylated or geranylgeranylated (23). After prenylation, the a1a2X sequence is 
excised by an endoprotease, and the prenylcysteine residue is carboxymethylated by Icmt 
(24). The resulting prenylated protein has high affinity for cellular membranes and 
possesses a unique structure that can serve as a specific recognition factor in protein- 
protein interactions (25-27).
Prenyltransferases are highly selective for their cognate isoprenoid diphosphates, 
and crystal structures have shown that these substrates bind along one side of the active 
site, with the diphosphate bound in a positively charged cleft in the pocket and the lipid 
tail extending deep into the pocket (21,28-37). Crystal structures of pGGTase I with 
GGPP and GGPP analogues reveal that the first three isoprene units bind in the pocket in 
the same way that the lipid moiety of FPP binds in the pFTase active site, while the 
fourth isoprene unit sits at a 90° angle relative to the rest of the lipid molecule, across the 
bottom of the active site (21,36,38). Moreover, the binding site for the first three isoprene 
units are essentially conserved in pFTase and pGGTase I. Placement of the observed 
binding conformation of GGPP in pGGTase I to the corresponding site in pFTase results 
in a steric clash with Trp102 and Tyr365, suggesting that these two residues are the key
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determinants of isoprenoid diphosphate specificity. Terry et al. subsequently showed that 
a Trp102Thr mutant, given the same threonine residue found in the corresponding 
position in pGGTase I, completely switched the specificity of pFTase from FPP to GGPP 
(39). Moreover, the turnover rate for the geranylgeranyl transfer reaction catalyzed by the 
Trp102Thr mutant is similar to that observed for farnesyl transfer by native pFTase. The 
mutation essentially abolished the use of FPP but retained the specificity for pFTase 
Ca1a2X protein substrates. Thus, through a single mutation, the isoprenoid specificity of 
pFTase was shifted without sacrificing catalytic efficiency. On the other hand, mutation 
of Tyr365 in pFTase to the corresponding residue in pGGTase I (phenylalanine) relaxed 
the isoprenoid selectivity of the mutant in that it could use both FPP and GGPP to 
prenylate typical pFTase protein substrates. Finally, a combination of the two pFTase 
mutations Trp102Thr and Tyr365Phe resulted in a variant with a kinetic profile similar to 
the one harboring only the Trp012Thr mutation. This mutant, as well as the Trp102Thr 
pFTase variant, could be used to elucidate the in vivo effects of alternate prenylation on 
cellular localization and function (39). Thus, structure-guided engineering of enzymes 
presents a powerful way to create proteins with new activities intended for practical uses.
The structures of IPK discussed in Chapter 2 revealed the amino acid residues that 
form the hydrophobic binding pocket of IP (40). Dellas and Noel first demonstrated in 
MJ IPK that transmutation of these side chains into less bulky ones, either singly or in 
combination, resulted in enzymes capable of phosphorylating the longer chain isoprenoid 
farnesyl phosphate (41). They also observed that the mutations are contextually 
dependent in that mutations in the back of the IP binding site were not effective without 
mutations at the front. The MJ IPK mutants were not kinetically characterized and their
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catalytic efficiencies for phosphorylation of farnesyl phosphate and geranyl phosphate are 
not known.
In vitro enzymatic studies by Thai et al. demonstrated the presence of kinase 
activities from Nicotiana tabacum microsomal fractions capable of converting farnesol to 
farnesyl diphosphate through successive monophosphorylation reactions (42). The 
evidence for an FP kinase is based on demonstrating that exogenous FP is converted to 
FPP by a CTP-dependent reaction, corroborated by the observation that CTP could be 
reversibly formed when microsomes were incubated with CDP and FPP or GGPP. Other 
farnesol kinases capable of producing FPP through a farnesyl monophosphate 
intermediate have been observed in 100,000 x g pellets from microalga (43), cell extracts 
from a halophilic archaeon (44), and microsomes from rat liver (45,46). In this chapter, 
several mutants of THA IPK with FP kinase activities, in conjunction with more 
pronounced geranyl phosphate (GP) kinase activities, are presented. Product analyses and 
steady-state kinetic characterizations were performed on these mutants, constituting the 
first direct demonstration of GP kinase activity to date. The work contained in this last 
chapter thus serves as a prelude to the creation of isoprenyl monophosphate kinases 
capable of labeling isoprenoid substrates with 32P, with applications in research involving 
isoprenoids and their derivatives.
Experimental Procedures
32Materials. y-[ P] ATP was purchased from American Radiolabeled Chemicals. 
Tricholoroacetonitrile (>95%), farnesol (95%), geraniol (98%), phosphoenolpyruvate 
(PEP) and nicotinamide adenine dinucleotide (NADH) were purchased from Sigma-
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Aldrich. Phosphoric acid (85%) was purchased from Reagents. Bovine serum albumin 
was purchased from Invitrogen. LDH (rabbit muscle) and PK (rabbit muscle) were 
purchased from Roche. The concentrations of all reagents containing phosphates were 
determined by phosphate analysis, and the precise concentration of mutant IPK enzymes 
were measured using the BCA Protein Assay Kit from Pierce.
Synthesis o f GP (2) and FP (3). The procedure by Keller et al. was used to 
synthesize GP and FP (47). Briefly, a dry solution of 3.46 g (17.4 mmol) 
triethylammonium phosphate (TEAP) in 15 mL of acetonitrile was added dropwise to a 
stirred mixture of alcohol (geraniol or farnesol, 3.25 mmol) in 5 mL of 
trichloroacetonitrile at room temperature under N2, in three equal portions with a 5 min 
interval between additions. The mixture was then concentrated at reduced pressure, 
giving a thick, dark orange oil. The resulting oil was chromatographed on silica gel using 
2-propanolINH4OHIH2O (6:3:1 vIvIv) and fractions containing pure products were 
combined. The solvent was removed by lyophilization, resulting in a white solid with a 
yield of 18%. Detection of GP and FP was performed by thin layer chromatography using 
the same mobile phase and stained with p-anisaldehyde, Rf (GP) = 0.47, Rf (FP) = 0.5. 1H 
NMR (D2O) for GP: 5 1.59 (s, 3H), 1.65 (s, 3H), 1.68 (s, 3H) 2.01-2.18 (m, 4H), 4.38 (m, 
2H), 5.17 (t, 1H, J=13.5 Hz), 5.42 (t, 1H, J=7.5 Hz); 31P NMR (D2O) for GP: 5 2.20. 1H 
NMR (D2O) for FP: 5 1.47 (s, 3H), 1.49 (s, 3H) 1.54 (s, 3H), 1.61 (s, 3H), 1.82-2.06 (m, 
8 H), 4.35 (m, 2H), 4.95-5.07 (m, 2H), 5.34 (t, J=6.7 Hz); 31P NMR (D2O) for FP: 5 3.94. 
The masses of the products were confirmed by major peaks for [GP-H+]- (233.1) and [FP- 
Na+]- (325.2) or [FP-H+]- (301.1).
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Mutation o f THA IPK. To create THA IPK mutants, computer modeling was 
performed using the UCSF CHIMERA software to dock GP and FP in the active site of 
THA IPK with in silico mutations (48). Mutations to create the desired mutants were then 
carried out using the QuikChange Lightning Multi-Site Directed Mutagenesis Kit 
(Agilent Technologies) and mutagenic primers designed using the Quikchange Primer 
Design Tool. The plasmid template contained the THA IPK gene in the pET28b vector to 
include the N-terminal sequence MGSSHHHHHHSSGLVPRGS upstream of the IPK 
sequence. Correct mutant sequences were confirmed by sequencing at the University of 
Utah DNA Sequencing Core Facility.
Expression and purification o f THA IPK mutants. Plasmids of mutant THA IPKs 
were chemically transformed into BL21 (DE3) Star cells (Invitrogen) and plated on agar 
containing kanamycin. Mutant colonies were used to make 10 mL starter cultures in LB 
broth, which were then inoculated into 1 L of LB medium. The cultures were shaken at 
37 °C until OD600 reached 0.5 and induced with 1 mM of IPTG followed by incubation 
overnight at 30 °C. Cells were harvested by centrifugation and stored at -80 °C until 
purification. For purification of THA IPK mutants, see Experimental Procedures in 
Chapter 3.
Detection o f GP and FP kinase activities using y-[32P] ATP. Purified THA IPK 
mutants were tested for GP, FP and IP kinase activities by incubating 10 ^M of each 
enzyme with 5 mM isoprenoid substrate in 100 mM HEPES buffer, pH 7.5, containing 10 
mM P-mercaptoethanol, 10 mM MgCl2, 1 mg/mL BSA, 1 .^M y-[32P] ATP for 2 hr at 37 
°C in a total volume of 50 ^L. The mixtures were quenched with 100 of 500 mM 
EDTA. A 10 ^L to 20 ^L portion of each incubate was spotted on silica plates and
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developed with CHCl3/pyridine/formic acid/ H2O (30:70:16:10 v/v/v/v). The TLC plate 
was imaged for 24 h using a storage phosphor autoradiography cassette and visualized 
using a Typhoon 8600 variable mode imager (GE Healthcare).
Kinetic characterization o f THA IPK mutants. The protocol for fluorescent assays 
was based on the procedure by Pilloff et al. with slight modifications (49). The activities 
of the coupling enzymes, PK and LDH, were measured using the procedure in Chapter 3. 
To initiate the reaction, a THA IPK mutant was added to the assay buffer (100 mM 
HEPES, pH 7.5, containing 10 mM MgCl2, 10 mM P-mercaptoethanol, 1 mg/mL BSA 
and 250 |jM ATP (saturating)), including appropriate amounts of GP, FP or IP and 
coupling enzymes in a final volume of 200 ^L. The reaction was monitored at 37 °C for 
600 s by observing the change in fluorescence (^ex = 340 nM, ^em = 460 nm) (FluroMax, 
Jobin Yvon Horiba). The initial rates were measured from the linear portion of the curve 
(< 15% consumption of the concentration limiting substrate). The kinetic constants were 
determined by fitting initial rates to equation 1 using nonlinear regression in GraFit5 (50, 
Erithacus Software)
V/[E] = kcat [S] / [S] + Km (1)
where V is the initial rate, [E] is the total concentration of enzyme in the mixture, [S] is 
the concentration of the isoprenoid substrate, and KM is the Michaelis constant. The 
concentration of ATP was chosen after performing similar experiments using saturating 
concentrations of the isoprenoid substrate.
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UPLC-MS o f THA IPK mutant products, GPP and FPP. Samples for UPLC-MS 
of GPP, FPP and IPP produced by THA IPK mutants were obtained by incubating 10 uM 
of each mutant with 2 mM of GP, FP, and IP (as control) in 100 mM HEPES buffer, pH 
7.5, containing 100 mM MgCl2, 10 mM P-mercaptoethanol, 1 mg/mL BSA and 5 mM 
ATP at 37 °C for 2 h. The mixtures were then centrifuged at 4 °C and 3000 rpm to 
remove the enzyme using a 10,000 MWCO Centricon (Millipore). The collected fractions 
were flash frozen and lyophilized overnight, then dissolved in minimum volume of 25 
mM NH4HCO3 . Isoprenoid diphosphate products (GPP, FPP and IPP) were separated 
from substrates (GP, FP and IP) on a C18 column (for GPP and FPP) and a C4 column 
(for IPP) on an Acquity UPLC. Isocratic elution with 95% 25 mM NH4 HCO3 and 5% 
acetonitrile was used to separate GPP and GP, while isocratic elution with 90% 25 mM 
NH4HCO3 and 10% acetonitrile was used to separate FPP and FP, each at a flow rate of 
0.6 mL/min. For the separation of IPP and IP, isocratic elution with 100% of 25 mM 
NH4 HCO3 was performed. Peaks with masses corresponding to each substrate and 
product were detected by negative-ion (ES-) MS.
Results
Mutation o f THA IPK and qualitative GP and FP kinase activity assays. A total 
of 8  mutants were created, initially using the pET151/D-TOPO THA IPK template from 
Chapter 2 used to crystallize and determine the structure of THA IPK. GP and FP in fully 
extended conformations were used in the in silico modeling for the identification of 
candidate mutations. The THA IPK variants contained different combinations of alanine 
mutations of the following residues in the periphery of the IP binding site: Leu58, Pro59,
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Tyr70, Val73, Val130 and Ile140 (40). The first two residues are found on the J33-P4 
hairpin that caps the IP binding site, Tyr70 and Val73 are found on the long aC helix, 
and Val130 and Ile140 are on the P9 and J310 strands, respectively (Figure 4.1a and b). 
Among these residues, Val73, Val130 and Ile140 are found at the front of the IP binding 
site, and based on inspection of the structure, mutation of these residues appeared to be 
necessary in order for mutations in the back to have any effect on the presumed binding 
of GP and FP in the enlarged pocket. The Tyr70Ala mutation appeared to be important 
to accommodate a fully extended FP molecule, while the Leu58Ala and Pro59Ala 
mutations were presumed to allow the binding of FP in the absence of the Tyr70Ala 
mutation. Table 4.1 lists the different mutants initially tested for GP and FP kinase 
activities. In the initial GP and FP kinase activity assays, crude purifications of these 
mutants were performed, owing to the difficulty of the pET151ID-TOPO constructs to 
yield homogeneous proteins. Moreover, the mutants appeared to express in different 
yields, such that in the initial activity assays, the total concentrations of mutant proteins 
used were not the same. Thus, the GP and FP kinase assays were qualitative estimations 
of activity (Figure 4.2a-4f). Based on the initial results of the GP and FP kinase activity 
assays, four mutants were chosen, namely Mutant 12, Mutant X, Mutant 7 and Mutant
11. These mutants appeared to have the strongest GP kinase activities among the 8  
mutants tested. Mutant 12, Mutant X, and Mutant 7 contain the Tyr70Ala mutation and 
were presumed to bind a fully extended FP molecule. Mutant 11 does not contain the 
Tyr70Ala mutation and was expected to have minimal FP kinase activity through binding 
FP in a nonlinear conformation. Among the four mutants, Mutant 12 has the biggest
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Figure 4.1. The THA IPK active site showing residues in the IP binding site mutated to 
alanine. (a) Side view of the THA IPK N-terminal lobe showing secondary structure 
elements that form the walls of the IP binding site and the chain length limiting residues. 
(b) Alternate view of the IP binding site.
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Table 4.1. List of engineered THA IPK mutants.
M utant name Combination of residues mutated to alanine
Mutant 6 Tyr70, Val130
Mutant 7 Tyr70, Val130, Ile140
Mutant 8 Leu58, Pro59, Tyr70, Val130, Ile140
Mutant 9 Leu58, Pro59, Tyr70, Val73, Val130, Ile140
Mutant 10 Leu58, Pro59, Val73, Val130, Ile140
Mutant 11 Val73, Val130, Ile140
Mutant 12 Tyr70, Val73, Val130 Ile140
Mutant X Tyr70, Val73, Ile140
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Figure 4.2. Autoradiogram showing product formation by THA IPK mutants incubated 
with GP, FP, and y-[32P] ATP. (a-b) Mutants 8, 7, 9, 6, 11 and 9 incubated with 10 mM 
GP and FP. The radioactive markers are the products produced by the incubation of avian 
FPP synthase with 14C-IPP and DMAPP. (c-d) Mutant X incubated with increasing 
concentrations of GP (c) and FP (d) for 2 hr at 37 °C. (e-f) Mutant 12 incubated with 
increasing concentrations of GP (e) and FP (f) for 2 hr at 37 °C.
b
FPP \
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substrate binding pocket as it contained all four Tyr70Ala, Val73Ala, Val130Ala and 
Ile140Ala mutations found in combinations of three mutations in the other three variants.
In order to obtain homogeneous enzymes for kinetic characterization, Mutant 12, 
Mutant X, Mutant 7, and Mutant 11 were subcloned into the pET28b vector, expressed 
and purified (Figure 4.3a). GP and FP kinase activity for each mutant were again tested 
(Figure 4.3b). All four mutants exhibited strong GP kinase activities, as shown by a 
strong radioactive spot corresponding to GPP (Rf = 0.52). In addition, Mutant 12, Mutant 
X, and Mutant 7, each containing the Tyr70Ala mutation, showed detectable FP kinase 
activities (lighter radioactive spot, Rf= 0.75) while Mutant 11 (no Tyr70Ala mutation) did 
not. For all mutants, GP kinase activity appeared stronger than either FP kinase activity 
or the residual IP kinase activity.
Kinetic characterization o f mutants and spectroscopic determination o f their GPP 
and FPP products. The coupled fluorescence assay by Pilloff et al. was used to measure 
the GP and FP kinase activities of Mutant 12, Mutant X, Mutant 7 and Mutant 11 (49). 
Table 4.2 summarizes the steady-state kinetic constants of all four mutants. The kinase 
reaction is bisubstrate and kcat and KM for one substrate were measured at a saturating 
concentration of cosubstrate.
Mutant 12 (Tyr70Ala, Val73Ala, Val130Ala, Ile140Ala). Mutant 12 exhibited 
improved GP kinase activity compared to wild-type IPK. Figure 4.4a shows a GP 
molecule docked in the active site of a modeled Mutant 12. For this mutant, kcat = 1.1 (±
0.6) s-1 represents a 22-fold increase relative to the GP kinase activity of wild-type THA 
IPK. In addition, KMGP = 2.4 (± 0.3) x 103 ^.M for Mutant 12, a slight change from KMGP 
for the wild-type enzyme. The catalytic efficiency kcat/KM = 4.7 x 10 , for the GP kinase
164
Figure 4.3. Purification of Mutant 12, Mutant X, Mutant 7 and Mutant 11 and product assay using y-[32P] ATP. (a) Denaturing SDS 
PAGE showing the four THA IPK mutants purified to homogeneity prior to use in enzyme kinetics. The masses of molecular weight 
markers are indicated. Monomeric THA IPK mutants have masses ~ 29 kDa. (b) Autoradiogram showing production of GPP and FPP 
by mutants, as well as the residual IP kinase activity forming IPP. The mutants were each incubated with 5 mM of isoprenoid 
monophosphate.
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Table 4.2. Kinetic constants for the kinase activities of THA IPK mutants.
WT THA IPK M utant 12 M utant X M utant 7 M utant 11
k J P (s'1) 0.05 1.11 (± 0.06) 4.04 (± 0.16) 10.08 (± 0.71) 2.80 (± 0.45)
kc/ V ) N. D. 0.62 (± 0.01) 1.40 (± 0.07) 1.48 (± 0.05) N. D.
kcatIP (s-1) 8.0 2.60 (± 0.10) x 10-3 1.01 (± 0.60) x 10-2 4.80 (± 0.30) x 10-3 1.09 (± 0.05) x 10-2
KmGP (|mM) 4.7 (± 1.3) x 103 2.35 (± 0.34) x 103 3.50 (± 0.34) x 103 7.96 (± 1.1) x 103 9.50 (± 2.67) x 103
KmFP (|mM) N. D. 1.82 (± 0.13) x 103 1.56 (± 0.26) x 103 1.50 (± 0.18) x 103 N. D.
K j P (|mM) 4.4 (± 0.5) 5.25 (± 0.75) x 103 7.90 (± 0.12) x 103 5.66 (± 0.88) x 103 4.24 (± 0.68) x 103
kcat/KMGP (M -V 1) 10.0 4.72 x 102 1.2 x 103 1.3 x 103 2.96 x 102
kcat/Km FP(M"1s"1) N. D. 3.40 x 102 8.83 x 102 9.87 x 102 N. D.
K J K m  ip ( m V ) 1.8 x 106 0.50 1.28 0.85 2.57
kcatATP (GP) (s-1) N. D. 1.45 (± 0.06) 1.45 (± 0.04) 1.18 (± 0.03) 1.32 (±0.03)
kcatATP (FP) (s-1) N. D. 1.26 (± 0.04) 1.65 (± 0.06) 1.10 (± 0.01) N.D.
kcaATP (IP) (s^) 6.3 (± 2.2) 1.09 (± 0.02) 1.44 (± 0.05) 1.06 (± 0.02) 1.48 (± 0.07)
KmATP (GP) (mM) N. D. 1.54 (± 0.45) 0.93 (± 0.23) 1.14 (± 0.23) 1.24 (± 0.22)
KmATP (FP) (mM) N. D. 1.32 (± 0.30) 1.36 (± 0.37) 1.16 (± 0.60) N. D.
KmATP (IP) (mM) 6.0 (± 0.5) 0.98 (± 0.18) 1.28 (± 0.29) 1.01 (± 0.12) 1.89 (± 0.49)
kca/KMATP (GP) ( M V ) N. D. 9.44 x 105 1.57 x 106 1.03 x106 1.06 x 106
kcat/KMATP (FP) (M -V 1) N. D. 9.51 x 10 5 1.21 x 106 9.44 x 105 N. D.
kca/KMATP (IP) ( M V ) 1.3 x 106 1.34 x 106 1.13 x 106 1.05 x 106 7.9 x 105
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Figure 4.4. Modeled GP (a) and FP (b) molecule in the Mutant 12 active site.
activity of Mutant 12, almost 50-fold larger than the GP kinase activity of the wild-type 
enzyme.
Figure 4.4b shows an FP molecule modeled in the active site of Mutant 12. The
kcatFP = 6.2 x 10-1 s-1 for phosphorylation by this mutant is two times lower than kcatGP by
the same enzyme. Since the GP kinase activity of wild-type THA IPK was very low, it
was presumed that the promiscuous FP kinase activity of wild-type THA IPK would be
negligible in comparison. The KMFP = 1.8 (± 0.1) x 103 ^.M for Mutant 12 to give a
2 -1 -1catalytic efficiency of 3.4 x 10 M s ,  which is comparable to the GP kinase activity of 
Mutant 12. This mutant also exhibited a measurable yet weak residual IP kinase activity, 
kcatIP = 2.6 x 10-3 s-1, which is 3100-fold lower than kcJ P for wild-type IPK. Moreover, 
Kmip = 5.2 (± 0.8) x 103 ^.M for Mutant 12 is 1200-fold higher than KMIP for wild-type 
THA IPK, resulting in kcat/KM = 5.0 x 10-1 M-1s-1, which is 3.6 x 106 - fold lower than for 
wild-type THA IPK. The Michaelis-Menten curves for GP, FP and IP are found in the 
Appendix.
ATP ATPThe kcat and KM for Mutant 12 using GP, FP, and IP as cosubstrates are 
similar to those for wild-type THA IPK (Table 4.2), leading to catalytic efficiencies
ATP ATPkcat /Km similar to those of the wild-type enzyme. The Michaelis-Menten curves for 
ATP in the presence of GP, FP, and IP as cosubstrates are found in the Appendix.
The ability of Mutant 12 to produce the isoprenoid diphosphate products from 
their respective isoprenoid monophosphate substrates was confirmed by ultra perfomance 
liquid chromatography and negative ion mass spectrometry. GPP produced by Mutant 12 
is evidenced by a sharp peak with a retention time of 1.11 min on a C18 column (See 
Appendix, M12 GPP). The GPP product was separated from GP substrate, shown by a
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smaller peak with a retention time of 3.39 min. The ratio of the peaks supports the high 
GP kinase activity of Mutant 12. The peaks correspond to a mass of 313 for the negative 
ion form of GPP (C10H 19O7P2-) and 233 for the negative ion form of GP (C10H 18O4P-).
Production of FPP by Mutant 12 is evidenced by a smaller peak with a retention 
time of 4.74 min, supported by a mass of 381 for its negative ion form (C15H27O7P2-). The 
substrate FP has a retention time of 5.43 min, and is supported by a mass of 301 for its 
negative ion form (C15H26O4P-) (see Appendix). Finally, we used a C4 column to separate 
IPP from IP in the incubation mixture with no success. Both compounds were found in 
the void volume with retention time of less than 1 min, but masses for the negative ion 
forms of IPP (245, C5H 11O7P2-) and IP (165, C5H 10O3P-) were detected (see Appendix). 
Mutant X  (Tyr70Ala, Val73Ala, Ile140Ala). Mutant X exhibited improved GP
GP 1kinase activity compared to Mutant 12 with a kcat = 4.1 (± 0.2) s' , which is 90-fold 
greater than kcatGP for wild-type THA IPK, and half of kcJ P for wild-type THA IPK. The
GP 3Michaelis constant, KM = 3.5 (± 0.3) x 10 ^M, is similar to that for Mutant 12 and
wild-type THA IPK, resulting in a catalytic efficiency, kcJKM = 1.2 x 103 M-1s-1 for GP
kinase activity that is 3-fold and 120-fold greater than those of Mutant 12 and wild-type
THA IPK, respectively. This GP kinase efficiency is only 103 lower than that of the
native IP kinase activity of THA IPK and represents a significant activity for GP relative
to native enzymes. The FP kinase activity of Mutant X is similar to that of Mutant 12,
where kcaF  = 1.4 (± 0.7) s-1 and KMFP is 1.6 (± 0.3) x 103 ^.M, leading to kcatIKM = 8.8 x 
2 -1 -110 M" s' only slightly lower than that of Mutant 12. Figures 4.5a and 4.5b show GP and 
FP molecules docked in the binding site of Mutant X. The Michaelis-Menten curves for 
the GP and FP kinase activities of Mutant X are found in the Appendix.
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Figure 4.5. Modeled GP (a) and FP (b) molecule in the Mutant X active site.
The residual IP kinase activity of Mutant X is slightly higher than that of Mutant
12 (kcat = 1.0 x 10-2 s-1, Km = 7.9 (± 1.2) x 103 ^M), with a catalytic efficiency, kca/K M = 
1.3 M-1 s-1 that is 1.3 x 106 -fold lower than wild type THA IPK. The Michaelis-Menten 
curve for the phosphorylation of IP by Mutant X is found in the Appendix.
Similar to the profile observed in Mutant 12, the mutations on the IP binding site 
did not affect the kinetic parameters for the use of ATP in the presence of the three 
different substrates. The kcats and KMs for the use of ATP by Mutant X are similar to 
those measured for Mutant 12 and native THA IPK, and the resulting catalytic 
efficiencies are similar to those of native THA IPK with an average of 1.3 M-1s-1 (Table 
4.2). The Michaelis-Menten curves for the use of ATP by Mutant X are found in the 
Appendix.
The formation of GPP and FPP upon incubation of Mutant X with synthesized 
substrates GP and FP was detected by UPLC and MS (see Appendix for MX GPP and 
MX FPP). A peak with retention time of 1.19 min on a C18 column, and a mass of 313, 
signals the presence of the negative ion form of GPP (C10H19O7P2-). This product is well 
separated from the GP substrate peak (retention time 3.81 min, mass 233 for the negative 
ion (C10H18O+P-). Moreover, a small peak with a retention time of 4.83 min and a mass of 
381 confirms the formation of FPP (mass 381, C15H27O7P2-), separated from the starting 
substrate FP with a retention time of 5.43 min and mass of 301 (C15H26O4P-). Finally, 
using a C4 column, the separation of IPP from IP was unsuccessful, although both 
species were detected in the void volume (retention times less than 1 min) with masses 
of 245 and 165 for the negative ion species C5H11O7P2- and C5H10O3P-, respectively (see 
Appendix).
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Mutant 7 (Tyr70Ala, Val130Ala and Ile140Ala). Among all four mutants tested, 
Mutant 7 has the highest turnover number, kcaGP= 10.1 (± 0.7) s-1, similar to kcJ p for 
wild-type THA IPK (8.0 s-1) and more than twice the activity of Mutant X. The kcatGP for 
Mutant 7 is also more than 200-fold greater than the promiscuous activity of wild-type 
THA IPK for GP. KmgP = 8.0 x 103 ^.M for Mutant 7 is slightly higher than for Mutant 
12, Mutant X, and wild-type THA IPK, leading to a catalytic efficiency of 1.3 x 103 M-1s-
1 3that is only 10 -fold lower than the catalytic efficiency of wild-type THA IPK for its 
native substrate, IP. The turnover number and Michaelis constant for FP by Mutant 7 is 
similar to that of Mutant X, with a kcatFP = 1.5 (± 0.1) s-1 and Kmfp of 1.5 (± 0.2) x 103 
^.M, leading to kcatIKM = 9.9 x 10 . Finally, the remnant IP kinase activity is also similar 
to those of the previous mutants, with low kcatIP = 4.8 x 10-1 s-1 that is almost 2000-fold 
lower than wild-type IPK. Kmip for Mutant 7 is also significantly higher (2000-fold) than 
that of wild-type THA IPK and similar to those measured for Mutant 12 and Mutant X. 
Figures 4.6a and 4.6b show Mutant 7 with bound GP and FP in the active site. The 
Michaelis-Menten curves for the kinase activities of Mutant 7 for GP, FP and IP are 
found in the Appendix. Unlike Mutant 12 and Mutant X, Mutant 7 was not saturated at 
12.5 mM GP. At GP concentrations of 12.5 mM or higher, precipitation was observed 
within 7.5 minutes of initiation with enzyme, making accurate initial rates impossible to 
obtain. Thus, the fitted Michaelis-Menten curve for Mutant 7 shows only initial rate 
points corresponding to GP concentrations less than or equal to 12.5 mM (Appendix). 
Since precipitation of FP was observed at concentrations higher than 9.5 mM, initial rate 
measurements were carried out at this FP concentration or lower. However, unlike when 
GP is used as a substrate, Mutant 7 reached saturation with FP before precipitation was
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Figure 4.6. Modeled GP (a) and FP (b) molecules in the active site of Mutant 7.
observed. Given these observations, the measurement of kinetic parameters for the use of 
ATP by Mutant 7 were performed at the highest possible GP (10 mM) and FP (7 mM) 
concentrations before precipitation was observed. Nevertheless, the kinetic parameters
ATP ATPkcat and KM for Mutant 7 remained consistent with those measured for wild-type 
THA IPK, Mutant 12 and Mutant X, with an average kcat/KM 1.0 x 106 M-1s-1. The 
Michaelis-Menten curves for use of ATP by Mutant 7 are found in the Appendix.
GPP produced by Mutant 7 was confirmed by UPLC-MS, corresponding to a 
single sharp peak with a retention time of 1.11 min and mass of 313 for the negative ion 
species, C10H 19O7P2-. A much smaller peak corresponding to the substrate GP 
(C10H 1gO4P-) was also found with a retention time of 3.37 min and mass of 233. The 
production of FPP by Mutant 7 was also supported by the presence of a small peak with a 
retention time of 4. 70 min and mass of 381 (C15H27O7P2-), separated from the strong FP 
peak with a retention time of 5.45 min and mass of 301 (C15H26O4P-). Finally, neither IPP 
nor IP was purified from each other using the C4 column, although masses for the 
negative ions species for both compounds were found at 245 (C5H 11O7P2- ) and 165 
(C5H 10O3P-) (see Appendix).
Mutant 11 (Tyr70Ala, Val130Ala, Ile140Ala). Among the four mutants, Mutant 11 
did not contain the Tyr70Ala mutation, resulting in a more compact substrate-binding site 
that was presumed to either not bind FP or do so with FP in a more compact 
conformation. However, this minimal mutation is sufficient to bind a fully extended GP
32molecule (Figure 4.7a). Product assays using y-[ P] ATP showed that the FP kinase 
activity of Mutant 11 was undetectable (Figure 4.2f). Thus, only the GP kinase activity of 
Mutant 11 was measured, in conjunction with the residual IP kinase activity. In addition,
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Figure 4.7. Modeled GP molecule in the active site of Mutant 11.
as in the case of Mutant 7, the GP kinase reaction did not reach saturation before 
precipitation was observed, so that initial rate measurements for the steady-state kinetic
GP -1investigations of this mutant were performed below 12.5 mM. The kcat = 2.8 (± 0.4) s 
for Mutant 11 reflects a 60-fold improvement to the turnover number of wild-type THA
GP 3IPK. Km = 9.5 (± 0.3) x 10 ^.M for Mutant 7 is the highest among all four mutants,
2 -1 -1leading to a catalytic efficiency for the phosphorylation of GP, kcJKM = 3.0 x 10" M V  
that is 30-fold larger than the catalytic efficiency of the wild-type THA IPK using GP. 
This translates to more than a 6000-fold decrease in catalytic efficiency compared to the 
native activity of THA IPK for its substrate IP. The Michaelis-Menten curve for the GP 
kinase reaction catalyzed by Mutant 11 is found in the Appendix.
The residual IP kinase activity of Mutant 11 is comparable to those of the other 
mutants, kcJ p = 1.1 (± 0.1) x 10-2 s-1 and almost a thousand-fold lower than that of wild- 
type THA IPK. Kmip = 4.2 (± 0.7) x 103 jjM  is also significantly higher than that of wild- 
type THA IPK. Thus, the catalytic efficiency for the phosphoryl transfer to IP catalyzed 
by Mutant 11 is 2.6 M-1s-1, more than 70,000-fold less than that for native THA IPK. The 
Michaelis-Menten curve for the IP kinase reaction catalyzed by Mutant 11 is found in the 
Appendix.
The kinetic constants for the utilization of ATP in the kinase reaction by Mutant
11 are very similar to those of other mutants as well as that of wild-type THA IPK, 
regardless of whether GP or IP was used as a cosubstrate. kcaf TP = 1.3 (± 0.1) s-1 for GP 
and 1.4 (± 0.1) s-1 for IP. KmATP = 1.2 (± 0.2) s-1 and 1.9 (±0.5) s-1, for GP and IP as 
cosubstrates, respectively. The calculated catalytic efficiencies, kcat/KM, are very close to 
that of wild-type THA IPK, at 1.06 x 106 M-1s-1 (GP) and 7.9 x 105 M-1s-1 (IP). The
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Michaelis-Menten curves for the utilization of ATP by Mutant 11 are shown in the 
Appendix.
Finally, as for the other mutants, GPP production by Mutant 11 was confirmed by 
a sharp peak with a retention time of 1.11 min, corresponding to a mass of 313 
(C10H19O7P2-). A smaller peak with a retention time of 3.48 min, corresponding to GP 
was also found, with a corresponding mass of 233 (C10H18O4P-) (see Appendix, M11 
GPP). Although separation of IPP and IP was not achieved using a C4 column, masses 
each corresponding to their negative ion species were found in the void volume: 245 for 
IPP (C5H 11O7P2- ) and 165 for IP (C5H 10O3P-) (See Appendix, M11 IPP).
Discussion
A total of 8 THA IPK mutants were created by the structure-based redesign of the 
THA IPK active site, with mutations at locations occupied by bulky amino acids in the IP 
binding site presumably influencing chain length specificity of this enzyme (40). Our 
goal was to create IPK variants that possess the ability to phosphorylate isoprenoid 
monophosphates longer than IP such as GP and FP. The mutants would be useful for
32synthesizing radiolabeled isoprenoid diphosphates with P in the P-position. These 
labeled compounds have many potential applications, including assays where isoprenoid 
diphosphates are substrates. In addition, these kinases can be used in vivo to recycle 
isoprenoid monophosphates from degradation of farnesyl diphosphate (41,51-52).
The redesign of IPK relied on the availability of an enzyme structure at good 
resolution. We were able to determine the structures of MTH and THA IPKs at 2.0 A 
(40). Kinetic characterization of both enzymes showed that the THA IPK homologs have
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comparable catalytic turnovers, with THA IPK being slightly better (53). With this in 
mind, we proceeded to create THA IPK mutants and characterized the kinetic behavior of 
those with the most prominent GP and FP kinase activities.
IP 3 IP 3For all mutants, Km increased 10 -fold while kcat decreased 10 -fold. The 
increase in Kmip might result from a corresponding increase in the size of the IP binding 
site that allows IP to bind in a variety of unproductive conformations. This in turn might 
cause the improper alignment of the terminal phosphate of IP relative to ATP, as well as
GPwith the catalytic residues in the IP binding site. In contrast, modest changes in Km 
were observed in the THA IPK mutants relative to that of wild type THA IPK, in 
conjunction with a 23- to 214-fold increase in the turnover number of GP. Thus, it 
appears that the expansion of substrate binding site allowed GP to orient better in the 
active site, leading to an increase in the productive catalysis for the mutant enzymes. 
Among the enzymes studied, Mutant 7, which contains the Tyr70Ala, Val130Ala and 
Ile140Ala mutations, has a kcaGP = 10.1 s-1 that is comparable to kcJ p = 8.0 s-1 of wild- 
type THA IPK (53). This mutant represents a good starting point for the development of a 
better “geranyl phosphate kinase” by means of further mutations to optimize the binding 
site for GP. The other mutants have comparable GP kinase activities, and the results of 
our product assays (autoradiography and liquid chromatography) showed almost 
complete conversion of substrates to products when 2 mM of GP and 5 mM of ATP were 
used, suggesting an equilibrium that favors GPP formation. Crystal structures of these 
mutants in complex with GP will help pinpoint additional mutations that can make the
GPgeranyl phosphate kinase activity more efficient by lowering Km through better binding 
of the substrate. It appears that the three mutants with the highest GP kinase activities
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(Mutant 7, Mutant X, and Mutant 11) have smaller substrate binding pockets than Mutant 
12, which seems to suggest that a bigger cavity does not necessarily translate to higher 
activity. Rather, the GP binding site must be just wide enough to accommodate a GP 
molecule while at the same time restricting it to one or a few binding poses suitable for 
catalysis.
We have also shown that the mutants containing the Tyr70Ala mutation (Mutant
12, Mutant 7 and Mutant 11) have secondary FP kinase activities that are lower than the 
observed GP kinase activities, supported qualitatively by product assays and 
quantitatively by kinetic measurements. Our modeling experiments showed that the 
Tyr70Ala mutation is necessary to bind a fully extended FP molecule in addition to 
mutations in the front of the IP binding site. However, FP can bind in several different 
different orientations through rotation around single bonds in the isoprenoid chain. Thus, 
although in autoradiography assays we did not detect FP kinase activity for Mutant 11, 
which does not contain the Tyr70Ala mutation, it is likely that this mutant also possesses, 
albeit weak, FP kinase activity that may become detectable under forcing conditions. A 
mutant of MJ IPK with similar mutations has FP kinase activity detected by the coupled 
IPK-sesquiterpene synthase assay, in which the formation of FPP by mutant IPK is 
coupled with tobacco 5-epi aristolochene synthase activity to form 5-epi aristolochene 
(41,54).
Our steady-state measurements showed that Mutant 12, Mutant X and Mutant 7 
have KMFPs that are lower than KMGP, which might suggest that a molecule of FP can bind 
better through more van der Waals interactions between its longer isoprenoid tail and the 
walls of the mutant active site. However, it might be oriented less optimally in the active
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site than a GP molecule due to its ability to interconvert among different conformations, 
leading to a lower kcat. The low FP kinase activities of these mutants are more than a 
hundred-fold higher than their residual IP kinase activities but at most 10-fold lower than 
their GP kinase activities. Thus, it appears that the mutants possess triple isoprenoid 
monophosphate activities, with GP kinase activity being the strongest among the three.
We have also observed that kinetic parameters for the utilization of ATP by the 
mutants are very similar to those of wild-type THA IPK, regardless of the identity of the 
cosubstrate. The catalytic efficiency of using ATP as a phosphoryl group donor is in the 
order of 106 M-1s-1 in the mutants as well as in the native enzyme. This is expected since 
the mutations were confined to the IP binding site, and there are no extensive interactions 
between the substrates aside from their terminal phosphate groups. There appears to be 
no cooperative substrate specificity as the N-terminal lobe, which binds the isoprenoid 
substrate, and the C-terminal lobe, which binds ATP, act independently of each other. 
This phenomenon has been observed in the conversion of human pFTase to pGGTase I, 
where the kinetic parameters for the Ca1a2X substrates of pFTase were not altered in the 
presence of change in substrate specificity from FPP to GGPP (39).
We have tested eight THA IPK mutants and further characterized four variants 
and observed significant improvements in GP kinase activities at the expense of native IP 
kinase activity. We have also observed FP kinase activities in three mutants that are 
inferior to their GP kinase activities. Thus, a directed shift in reaction specificity from 
IPK to GPK has been accomplished, and to our knowledge, this is the first instance in 
which an artificial GPK was reported and partially characterized. Dellas and Noel 
reported the conversion of a thermophilic IPK homolog to FPK, although the activity
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toward FP was not established (41). Other groups have reported the presence of isoprenol 
kinases able to catalyze the successive phosphorylation of farnesol and geranylgeraniol 
using ATP, GTP, UTP and CTP, to form FPP and GGPP in a probable salvage pathway 
for recycling isoprenoid alcohols (43-46,55). Despite this accomplishment, there exist 
many other possible IPK variants that can bind different conformations of GP and FP that 
need to be identified, and where the high-throughput coupled kinaselterpene synthase 
assay suggested by Dellas and Noel would be ideal for rapid and qualitative analysis. In 
addition, the mutations performed in this work were X to Ala mutations. It would be 
interesting to see what other types and combinations of mutations would yield engineered 
IPKs with the highest isoprenoid monophosphate kinase activities. Finally, similar 
mutational studies on mesophilic homologs of IPK could exhibit improvements in 
catalytic properties of engineered enzymes targeted for characterization and practical 
application at ambient temperatures.
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1H and 31P NMR Spectra of IP, GP and FP 
MS/MS Fragmentation of IPK and FomA Product Fosfomycin Phosphate 
MS/MS Fragmentation of Fosfomycin Standard 
UPLC- MS of Mutant 12, Mutant X, Mutant 7, and Mutant 11 Products 
Michaelis-Menten Curves for Mutants 12, Mutant X, Mutant 7 and Mutant 11, using GP,
FP, IP, and ATP as Substrates
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Michaelis-Menten curves for Mutant 12 using GP (a), FP (b) and IP (c) as substrates at 
250 |^M ATP.
208
Michaelis-Menten curves for the use of ATP by Mutant 12 using 10 mM GP (a), 7 mM
FP (b), and 20 mM IP (c) as cosubstrates.
209
Michaelis-Menten curves for Mutant X using GP (a), FP (b), and IP (c) as substrates at
250 |^M ATP.
210
Michaelis-Menten curves for the use of ATP by Mutant X using 10 mM GP (a), 7 mM FP
(b), and 20 mM IP (c) as cosubstrates.
211
Michaelis-Menten curves for Mutant 7 using GP (a), FP (b), and IP (c) as substrates at
250 |^M ATP.
212
Michaelis-Menten curves for the use of ATP by Mutant 7 using 10 mM GP (a), 7 mM FP
(b), and 20 mM IP (c) as cosubstrates.
213
Michaelis-Menten curves for Mutant 11 using GP (a) and IP (b) as substrates at 250 ^M 
ATP.
214
Michaelis-Menten curves for the use of ATP by Mutant 11 using 10 mM GP (a) and 20
mM IP (b) as cosubstrates.
